Novocure Ltd. Aktie

Good day, and welcome to the NovoCure Q3 2026 Earnings Call. [Operator Instructions]

Please note, this call may be recorded. I would now like to turn the call over to Adam Daney. Please go ahead.

Good morning, and thank you for joining us to review NovoCure's third quarter 2026 performance. I'm joined on the phone today by our Executive Chairman, Bill Doyle; CEO, Frank Leonard, Chief Innovation and Medical Officer, Uri Weinberg; and CFO, Christoph Brackmann.

For your reference, slides accompanying this earnings release can be found on our website, www.novocure.com on the Investor Relations page under Quarterly Results. Before we start, I would like to remind you that our discussions during this conference call will include forward-looking statements, and actual results could differ materially from those projected in these statements.

These statements involve a number of risks and uncertainties, some of which are beyond our control and are described from time to time in our SEC filings. We do not intend to update publicly any forward-looking statement, except as required by law. Where appropriate, we will refer to non-GAAP financial measures to evaluate our business and specifically adjusted EBITDA, a measure of earnings before interest, taxes, depreciation, amortization and share-based compensation.

We believe adjusted EBITDA is an important metric as it removes the impact of earnings attributable to our capital structure, tax rate and material noncash items and best reflects the financial value generated by our business.

We do not provide forward-looking guidance for adjusted EBITDA on a GAAP basis due to the inability to predict share-based compensation expenses contained in the reconciled GAAP measure, net income without reasonable efforts.

Reconciliations of non-GAAP to GAAP financial measures are included in our press release, earnings slides and in our Form 10-Q filed with the SEC today. These materials can be accessed from the Investor Relations page of our website. Following our prepared remarks, we will open the line for questions. I will now turn the call over to our Executive Chairman, Bill Doyle.

Thank you, Adam. This morning, NovoCure reported results for the third quarter of 2026. This quarter was marked by solid execution with continued momentum in our Optune Gio business and our promising launch of Optune Lua in Japan. We reached a record number of active patients on therapy, generated record high quarterly net revenue, and made strong progress on our path to profitability.

We experienced headwinds in our Optune Pax launch this quarter, but remain committed to establishing TTFields therapy in the evolving PDAC standard of care. As we enter the final months of the year, we are on track to achieve our 2026 goals, and we believe we are well positioned to drive this positive momentum into 2027.

I will begin this morning with a review of our Optune Gio and Optune Mya programs. Frank will provide an update on Optune Pax and Optune Lua, and Christoph will conclude our prepared remarks with a review of our third quarter financial results and updated guidance. We will then open the line for questions.

Q3 was another strong quarter for our Optune Gio business. We finished the period with 4,729 GBM patients on therapy, an 11% increase year-over-year and our highest GBM active patient count to date. A notable feature of this growth cycle is the mix of contributions from both new and established markets. We continue to believe many more patients can benefit from Optune Gio, and we are determined to find the avenues to reach them.

Each of our active markets has opportunities to increase adoption in GBM, and our country-level teams are focused on improving outreach and targeting to connect with physicians and patients at the optimal points in their treatment journeys. Optune Gio is a standard of care for newly diagnosed GBM, established on the foundation of the best-in-class clinical data for overall survival. And we are working to extend survival further.

Our Phase III KEYNOTE-D58 clinical trial is evaluating adding the immunotherapy pembrolizumab to Optune Gio and low-dose chemotherapy in diagnosed glioblastoma. We've been pleased with the strong interest in D58 since launch as physicians are eager to see whether concomitant use of TTFields and immunotherapy can improve survival in GBM further. D58 remains on track to complete enrollment by year-end, and we look forward to sharing more information from this trial in the periods ahead.

Turning to Optune Mya, our PMA application for the treatment of brain metastases from non-small cell lung cancer is under review with the FDA. As a reminder, this application is based on the data from the Phase III METIS trial, which showed a doubling in time to intracranial progression in patients on the TTF arm compared to control.

We continue to expect a final decision on our PMA application by year-end with a potential launch in early 2027. As with our other launches, we expect to establish reimbursement within two years of launch.

NovoCure continues to grow and evolve. We have reignited growth in our core GBM business and launched Optune Lua and Pax in multiple countries, with Mya expected to follow. We've established the infrastructure to service larger patient populations and have initiated structural changes to accelerate our transition to profitability. I'll now pass the call to Frank to discuss the ongoing launches of Optune Pax and Lua.

Thank you, Bill. We believe that we have multiple drivers of long-term growth, including increasing adoption of Optune Gio, successfully launching new indications like Optune Pax and Mya and pursuing opportunistic launches such as the Optune Lua launch in Japan. We are 2.5 quarters into our launch of Optune Pax, and we finished the third quarter with 276 active patients on therapy and generated $3.7 million in net revenue.

We have seen momentum slow in the U.S. due to the introduction of daraxonrasib. Our ability to access practices to detail Optune Pax is significantly limited at this time. We acknowledge the challenges in the Optune Pax launch, and we will continue to evolve our tactics to ensure we maintain our share of voice in our approved indication, which is different than the approved indication for daraxonrasib.

We will also continue to monitor the details of the daraxonrasib launch and invest appropriately in relation to the market realities. We look forward to the upcoming annual update of the NCCN guidelines for the treatment of pancreatic cancer, and we'll update our marketing materials accordingly.

Most importantly, we will work closely with our physician collaborators to establish the best next set of clinical trials to establish TTFields more firmly as the standard of care for PDAC.

We are specifically eager to generate data focused on concomitant use of TTFields and KRAS inhibitors. The initial step in this effort will be through two small safety and feasibility trials. The PANOVA-5 trial will explore the concomitant use of Optune Pax, gemcitabine, nab-paclitaxel and Verastem's KRAS G12D inhibitor, VS-7375 in our approved locally advanced setting. We are excited to collaborate with Verastem in this effort and expect to initiate this study in the first half of 2027.

The PANOVA -6 trial will explore concomitant use of Optune Pax and daraxonrasib in the metastatic setting, which we also expect to initiate in the first half of 2027.

Moving to Optune Lua. We continue to see momentum in our launch in Japan. We finished the quarter with 255 Optune Lua active patients and $8 million net revenue globally, with 110 active patients and $4 million in net revenue contributed by Japan. Second-line use of immune checkpoint inhibitors is standard of care in Japan, which overlaps well with our label and the strongest outcomes from the LUNAR trial data.

In addition to the promising commercial landscape, the negotiated monthly price for Optune Lua in Japan is approximately in line with our global price for Optune Gio. Optune Pax was also approved by Japanese regulators earlier this year with reimbursement likely in the first half of 2027. Together with our growing Optune Gio business, we expect Japan will eventually be our second largest market behind the U.S.

As Bill said earlier, we focused in recent years on diversifying and expanding our growth drivers. We are beginning to see those drivers contribute, specifically in our continued Optune Gio growth and Optune Lua launch in Japan. We expect Optune Pax to return to growth in the coming quarters. And with these drivers in place as well as enhanced controls on operating expenses, we believe we are well positioned to make material strides forward in our path to profitability next year. I'll now pass the call over to Christoph to review our third quarter financials.

Thank you, Frank. This was a very strong commercial quarter. We generated $193 million in net revenue, an increase of 16% year-over-year. This includes contributions of $8 million and $4 million from Optune Lua and Optune Pax, respectively. The increase in net revenue was primarily driven by a 19% year-over-year increase in active patients as well as a onetime benefit of $4 million from increased approval rates in the U.S. and Germany. We also experienced a $2 million headwind from foreign exchange rates in the quarter.

Based on our strong commercial performance this quarter, we are raising our revenue guidance. We now expect 2026 net revenue between $736 million and $743 million, representing 12% to 13% growth. This includes net revenues from Optune Lua and Optune Pax collectively between $30 million and $34 million.

Gross margin for the quarter was 77% compared to 73% in Q3 of last year. An important aspect in our pursuit of profitability is optimizing our supply chain efficiency as we treat larger patient populations, and we continue to see progress on these initiatives. We expect to maintain our gross margin in the mid- to high 70s through the final quarter of 2026.

Turning to our operating expenses. Research and development costs this quarter were $58 million, an increase of 8% year-over-year. The increase was primarily driven by expenses related to our KEYNOTE-D58 trial as we finalize enrollment.

R&D expenses can fluctuate quarter-to-quarter, largely around clinical activity for services delivered in the period. We are confident that we can keep R&D costs roughly at or below current levels for the foreseeable future.

Sales and marketing expenses in the quarter were $53 million, a decrease of 9% from the same period last year. The change was primarily driven by lower share-based compensation and lower general marketing expenses in the quarter. As we look ahead to Q4 and 2027, we intend to largely leverage our existing sales forces.

We do expect to make limited incremental marketing investment intended to support the launches of Optune Pax and Optune Mya.

General & Administrative Expenses for the quarter were $44 million, a decrease of 5% year-over-year. The primary driver of the decrease was lower share-based compensation expenses. We have made the G&A investments required to support larger patient populations, and our aim is to maintain the current level of G&A with minimal increases due to inflation.

Net loss in the quarter was $10 million compared to a $37 million loss for Q3 of last year and loss per share was $0.09. Our EBITDA loss in the quarter was $2 million compared to a loss of $32 million in Q3 of 2025.

Adjusted EBITDA, which removes the impact from share-based compensation was positive $16 million this quarter compared to a negative $3 million of last year. We are updating our full year adjusted EBITDA guidance today to a range of $24 million to $34 million.

Our cash and investment balance as of September 30 was $463 million. Our focus on profitability has been a key performance metric for the entire organization in 2026, and we are pleased with the progress made this quarter. The third quarter marked a new record high net revenue generated and our strongest EBITDA and adjusted EBITDA quarter in over four years.

The investments necessary to launch new indications and support larger patient populations have largely been made. As we continue to gain traction across our commercial portfolio, we believe there is significant P&L leverage to be realized. Achieving adjusted EBITDA positivity this year is an important first step in the profitability journey, and we look forward to updating you on our progress and future objectives in the coming months.

With that, we will now open the line for your questions.

[Operator Instructions]

Our first question comes from Vijay Kumar with Evercore ISI.

Frank, maybe my first one on Pax trends. And I know in the past, you've said this is not like a drug launch. Don't expect script volume similar to drugs. And I understand that, but sequential step down here on patients and script volumes, right? If you could just elaborate on what happened in the quarter? How are we thinking about Pax launch, I think that will be helpful.

Yes. Thank you, Vijay, for the question. It's clear, we had a record quarter overall in terms of our commercial execution, as Christoph just detailed, really strong progress across Gio around the world as well as our Japan launch. But it is clear to us that we faced significant challenges in the U.S. Pax launch this quarter. To give a little bit of color, I think we all need to think about just the sheer volume of patients now coming into practices and asking for daraxonrasib.

And that has an immediate effect on the practice in a few different ways. I mean, one is that immediately, the insurance appeals start. And I think as some on the line are tracking, the journey for daraxonrasib through the insurance process is just starting. And on the other side, as the patients progress on therapy, they do see a lot of skin irritation.

So what we face in terms of getting into practices right now is really just a share of voice issue as we see it right now that the practices are just a bit overwhelmed. They're overwhelmed with appeals, they're overwhelmed with skin irritation. But we do see that continued interest when we engage with clinicians in explaining Optune Pax.

So to look ahead, we are committed to this market. We still see strong recognition of the clinical value of Optune Pax as a first-line treatment in locally advanced pancreatic cancer. And we are eager to see this early disruption kind of the practice disruption settle down in the coming quarters and give us a chance to really get back in there and earn the patients that could really benefit from Tumor Treating Fields.

Understood. Maybe Christoph, one for you. Adjusted EBITDA performance here in the quarter was really a standout. Sustainability of this level of sequential improvements in adjusted EBITDA. I mean what's the path forward when you think about adjusted EBITDA trends?

Yes. Thank you, Vijay. Yes, you said it. I mean, we had a very strong quarter of financial performance, both across all lines really on the P&L, right? I mean, starting with revenue growth, very strong revenue growth based on active patient growth, but also with some onetime benefit. We had strong gross margin, relatively lower cost to previous quarters. And all of that culminated in a record high EBITDA and adjusted EBITDA. So the first comment is, as we said in the past, we are really committed to this path of profitability, and we always said for us, it's three steps.

Step 1 is to get adjusted EBITDA breakeven.

Step 2 is then cash flow breakeven, step 3 is net income breakeven.

And we are very happy that we passed the first step, and we are committed to adjusted EBITDA breakeven if you look at it on a full year basis.

Now I would caution, we will have some fluctuations quarter-to-quarter. You can also take from our guidance for adjusted EBITDA that we're not just straight line projecting a quarter-over-quarter increase, but we gave ourselves some room. One is on -- we have a range on revenue for our guidance, but then two is also now with Q4 coming up. It's typically a difficult quarter to estimate because we are getting ready for launches for next year.

So in short, we are committed to adjusted EBITDA breakeven. We are committed to really focus on the next call is cash flow breakeven, but I wouldn't want to commit to a straight line on a quarter-to-quarter basis.

Our next question comes from Larry Biegelsen with Wells Fargo.

So one on 2027, one on Pax. So Frank, I think at our healthcare conference, you talked about striving for double-digit growth in 2027. Is that still the case? And can you talk about the headwinds and tailwinds behind the outlook?

Thanks, Larry. Yes. So as we've talked about the future of NovoCure, what we have aspired to be is a company that produces double-digit top line growth and returns to profitability, as Christoph just outlined. We were really pleased in this quarter to have delivered double-digit growth, both when you look at all products together, but even in the Gio franchise, where existing markets like the U.S. were growing strong, and we found new markets to continue building like Spain.

I think that our commercial organization is really firing on all cylinders right now. And where there's opportunity, they're taking it. And I think I'm quite proud of those results. So yes, that's our vision is we remain committed to delivering that top line double-digit growth into the future.

That's helpful. And Japan was obviously very strong again this quarter. What are your expectations for Lua and Pax? Just remind us of the time line for reimbursement there. We saw, obviously, you got approval and remind us why this is an exciting opportunity.

Thank you, Larry. And I realize I missed the very end of your question. I didn't answer the very end of your first question here. In terms of possible tailwinds or real tailwinds for the company overall, our business in Japan is definitely one of those tailwinds. We have launched Optune Lua successfully, continued to build our active patient volume through the year this year.

We are already looking ahead to next year where we have our national symposium with all of the relevant physicians who treat non-small cell lung cancer in Japan coming into Tokyo to do a symposium just focused on Optune Lua in January. So we see that strong continued interest for Lua to continue growing in Japan.

Optune Pax was just approved for regulatory approval in the quarter, and we expect to have reimbursement early in 2027, first quarter of 2027, which would then allow us to begin the launch in Optune Pax. And as a reminder, for both of these products, we were able to reset our price levels with the MHLW in Japan. Both Lua is already priced at a higher level than our Gio product in Japan. And we're hopeful that we'll be able to achieve a similar outcome for the Pax product as it comes to market.

So the last thing I'll say is just to remind everyone in Japan, historically, our business in Japan has appeared relatively small, relative to the rest of the company because the incidence of GBM is very low in Japan. That's not the case for lung cancer. And in fact, in pancreatic cancer, it's actually a higher incidence than in the U.S. So these are real sizable markets with strong physician interest, and we are very excited for our Pax launch in Japan.

Our next question comes from Jason Bednar with Piper Sandler.

I'll ask the obligatory question here on Optune Pax as well. Just curious, Frank, I mean, I guess, what are you able to control with the process here? And when we think about the accounts you had that were initial users of Pax are they still using? Or did activity -- prescribing activity more or less dry up after the approval? And sorry, I'm going to add another one. Is this an issue you think of practices simply being overwhelmed and they don't have time? Or are you seeing just a lot of practices putting both locally advanced and metastatic PDAC patients on therapy?

Okay. Thank you, Jason. Yes, I'll jump in on the second part of this. That's obviously our focus right now is trying to understand what has caused the slowdown in prescribing patterns. We're looking at it both quantitatively in terms of buying data and qualitatively in terms of speaking with physicians. And first and foremost, what I want to highlight is that we're not seeing patients leaving Optune Pax in substantial numbers to start daraxonrasib.

And when we look at qualitative and quantitative data as well, we don't see strong signals that daraxonrasib is being used widespread in first line, except in the patients where they can't tolerate standard chemotherapy. So that leads us back to the hypothesis that we see the practices as just being simply overwhelmed right now and that is what's limiting our ability to get in.

As we spoke briefly about earlier in the call, again, this is a device-based launch. practices need training, they need support. They need help educating the patient. So we do see this as a bit of -- right now, we see it as an issue with the noise of getting into the practice. What can we control? I think first and foremost, we are as an organization, we remain committed to this indication, and our teams know we're committed to the indication, and we are continuing to get as much as we can to get to our physicians.

On that front, I would highlight one of the really promising signals that I picked up recently is I just came back from the ESMO conference in Madrid, we had incredible engagements with physicians across all of our indications. But when I look back at the numbers from the booth of unsolicited inquiries, the #1 product that led to inquiries in our booth was Optune Pax.

So that's where we feel that the recognition of the clinical value is still there. It is up to us to execute with our teams in the field, getting that message out and highlighting the different indications, different stage of treatment that our product is approved for. And then lastly, as we announced yesterday and spoke about today, we are going to continue building the evidence to support and consolidate our status as a valuable and standard of care treatment for PDAC.

Right. Very helpful and very clear. One follow-up quick and then a separate question. I'm not sure if I caught where you're at with respect to commercial payers on Optune Pax. Sorry if I missed that, but refresh me there. And then on R&D, obviously, a little bit of a step-up in the quarter, but you're coming to the close of KEYNOTE-D58. How should we think about R&D trending as we move beyond '26 once that KEYNOTE D58 trial ends? I know you got a couple of earlier-stage trials, but those should be far cheaper than KEYNOTE-D58.

Yes. Jason, I'll start and then I'll turn it over to Christoph. In terms of our payer engagement in the U.S., the next major milestone for us is to secure inclusion in the NCCN guidelines. The NCCN guidelines for pancreatic cancer are typically published once a year, either at the end of the year or early in the new year.

We have submitted. We understand that we've been reviewed, and we're eagerly waiting for those results to be published. That will trigger additional engagement with payers where we've already had and reported on our one success with Elevance, where we now have a coverage policy in place. Christoph, I'll turn it over to you to talk about any other emerging trends with payers as well as the R&D question.

Yes. I think on the payer side, I mean, as you noted, I think the real next milestone is NCCN guideline. And apart from that, we are having the discussions with the payer on the commercial side on the inclusion in policies. Obviously, this is a function of, one, the number of patients on therapy that helps us to mess and build pressure with payers and then two, the guideline inclusion is an important factor for that as well.

On the R&D question, Jason, so from a big picture perspective, 2026, we had larger Phase III trials roll off, as you know. And then we had particularly D58 now being close to full enrollment is really at the, let's say, highest level of activity and from that also from a spend intensity perspective at the highest level.

That essentially replaced the studies that we had that were rolling off. For 2027, we expect D58, but also LUNAR-2 still be a significant portion of our spend. So as we said, we expect our R&D expenses flat to slightly declining. And then going beyond that time frame, as large Phase III trials roll off, namely D58 and LUNAR-2, we would expect our R&D expense to go down if we don't replace it with other larger trials.

Our next question comes from Jessica Fye with JPMorgan.

This is Tanmay on for Jess. I have a question around the updated total revenue guidance. And when I was calculating, I saw that your revised annual revenue guidance now implies $185 million to $192 million in 4Q revenue, which is below the $193 million revenue recorded in 3Q. So can you talk about what assumptions are driving this sequential step down?

Yes, I can take this. So maybe I share a bit more thoughts on our revenue guidance in general. First, Q3 was really a very successful quarter in terms of net revenue, adding about $9 million of revenues to what we had as a record quarter in Q2, right? So thinking about Q4 revenue guidance, if we do in Q4, what we did in Q3, less the $4.4 million onetime revenue in Q3 that we pointed out, that essentially gets you to $740 million, which is around the midpoint of our guidance. And that was the thinking here. And then we accounted for some potential risk on collection side and some opportunities that we have.

Our next question comes from Kevin DeGeeter with Ladenburg Thalmann.

I just had one on the Verastem collaboration or a clinical trial you announced yesterday. And from the NovoCure perspective, what's the more important learning from that study? Is it really kind of appreciating the patient sort of antitumor clinical benefit of a combination with the KRAS inhibitor? Or does it really learn more about how the skin toxicities kind of play together? I just kind of want to understand, I guess this is an NovoCure-funded study kind of from your perspective, what are we trying to learn?

Excellent. Thank you for the question. I'll start off, and then I'll turn it over to my colleague, Dr. Weinberg, to speak to some of the specifics of the trial. First, I just want to note that we are very pleased to have this collaboration in place with Verastem. We think that this asset has the potential to be best-in-class, and we are excited to work with them. I think I would also highlight that I think this trial being done in locally advanced pancreatic cancer, first line, which is our FDA-approved indication, is strong validation of Tumor Treating Fields as an effective therapy in that indication already. And that really drove our ability to get a top-tier partner to work with us on a study here. So my thanks to our partner, our collaborators at Verastem. And I'll turn it over to Dr. Weinberg to talk a little bit about what we hope to see and how it dovetails off some of the things we've already seen in preclinical research.

Thank you. So the PANOVA-5 study is going to focus on our approved indication in pancreatic cancer, namely locally advanced unresectable patients. And it will incorporate the Verastem's G12D VS-7375 inhibitor, KRAS inhibitor concomitantly with gemcitabine, nab-paclitaxel and of course, Optune Pax.

This study will include around 25 patients. And we have also announced that we are opening the PANOVA-6 study that will use daraxonrasib in its approved indication of metastatic pancreatic adenocarcinoma concomitantly with Optune Pax enrolling a similar number of patients. So we are being very attentive to the developments in the field and dynamic in our approach to that, considering everything that we have done in pancreatic cancer so far.

And these two smaller single-arm studies intend to give the first experience showing feasibility and tolerability and toxicity of the concomitant use of Optune Pax with KRAS inhibition in the disease. And as you mentioned, the first and foremost goal of these two studies is to give physicians with the right level of confidence and experience to see the feasibility of this.

We will learn about toxicity, but we're not particularly concerned about this considering the local nature of our therapy and the nature of the skin toxicity that we observed so far in pancreatic adenocarcinoma. And I would just remind everybody that preclinically, we have seen a very important activity of TTFields affecting downstream transcription factors to KRAS, which suggests that the concomitant use of our device with KRAS inhibitors of any kind might be very interesting and even could be synergistic, hopefully.

I'm showing no other questions. I'd like to turn the call over to Bill Doyle for closing remarks.

Thank you very much. I'd like to conclude today with a big thank you to the NovoCure team. This was an exceptionally strong quarter. And as Frank noted, it was strong across the board. Our emerging markets performed very well. But importantly, our established markets really showed growth across the board.

We've said for years that there are many more patients who can benefit from Tumor Treating Fields than have been currently prescribed. And our teams have begun to figure out the ways to get to those patients and their clinicians at the moment that decisions are made so that they can benefit from the therapy, and we saw it in the numbers.

We're focused on Pax, as you described. There's a tremendous amount of change in the pancreatic market. We're all aware of this. As Frank described in detail, it's creating quite a bit of work within the practices. And that work involves learning how to use the new therapy, learning how to guide patients through the reimbursement process. But we also know that the KRAS therapies are not cures, and we're going to see a wave of recurrence later this year as well if the data that we've seen in the clinical trials bears out, which we expect it to.

That's where we're really going to see, I think, the opportunity to, one, get back into the practices, but really find the sweet spot for Tumor Treating Fields in this emerging landscape, along with the activities that Uri described, really studying the concomitant use of the therapies together. And then finally, we are a company that's committed to profitability. And I think we have shown tangible progress on that path over the last few quarters. And we're very pleased to be able to increase our guidance, both in terms of revenue, but importantly, in terms of adjusted EBITDA today. So thank you very much for your interest in NovoCure, and we look forward to our next report.

Thank you for your participation. This does conclude the program. You may now disconnect. Good day.

Good afternoon, everyone. I'm very happy to be here on the first day of the Morgan Stanley Healthcare Conference joined by the management team of NovoCure. I'm sitting here with CEO, Frank Leonard, and CFO, Christoph Brackmann. Thank you both for joining us here today. Hope you had a great day of meetings.

Just a quick research disclaimer. You can see our research disclosures at morganstanley.com/researchdisclosures.

So Frank, let's start with just a high-level overview of NovoCure and where you guys sit today. For anyone following along that isn't familiar with the story, maybe you can just give a brief overview of the company and what you're trying to achieve.

Yes, absolutely. And Kelly, thanks for having us here today. We've had a great day at the Morgan Stanley conference. NovoCure as a company was founded a little bit over 25 years ago in Israel, and it was a classic story of innovation where a founder had a unique insight into how to disrupt cancer cell division using electric fields. The technology over the course of 25 years was advanced through multiple Phase III programs, roughly $1 billion worth of research and development and has really been shown, especially in glioblastoma, to have definitively changed long-term survival for cancer patients.

So the way that I like to think about NovoCure at this stage is that we've spent the first 25 years taking a really novel approach to killing cancer cells. And again, it's electric fields, which we can talk more about, applied in a way that they haven't been used before, such that it's very low-to-no toxicity, no systemic toxicity effectively, but the ability to target multiple different types of cancer. And we've kind of crossed from the start-up phase of the company to now where we are built -- we've built out a global sustainable business. And the question now is where can we best apply Tumor Treating Fields to help extend survival.

Great. And Frank, you took over as CEO in late 2025. What are some of just the strategic changes that you've implemented since sitting in the seat?

Yes. Thank you. I've been joined through this process by Christoph, who -- we've really been side by side and that we came into a really promising technology and an engaged and wonderful team at NovoCure. But I think what we lacked coming into the start of this year was really the focus and the discipline on where are we going to invest, where are we not going to invest? And moreover, for our existing business treating glioblastoma, how are we going to return that franchise to growth.

So I think coming into this year, our major priorities were: one, find a way to grow the number of patients using the device to treat glioblastoma. Two is finding the best way to launch in our new indications, treating pancreatic cancer and non-small cell lung cancer, specifically non-small cell lung cancer in Japan. And then three, we also needed to take a hard look at some of our operating expenses and make sure, particularly on the R&D line, that we were investing in a way that would lead to an appropriate return on capital.

And I'm pleased to say that we've accomplished all 3 of those initiatives through the first half of the year. And moreover, I think one of the other major changes we've made is that we've begun issuing guidance for the first time in company history so that we can really have a much more streamlined conversation with our investors.

I want to go a little bit further into one of the points you made, which is this return to growth in GBM. Optune Gio, this is your most advanced commercial franchise, right, in GBM. So Optune Gio has now been on the market for over 10 years. You did have a little bit of a moderation in growth in recent years, but now you've had several strong quarters in a row. So how did you guys reignite that growth in the business? And I don't want to gloss over that point that you made.

Thank you. Well, I'm happy to talk about it. Optune, as Kelly noted, Optune Gio was approved for newly diagnosed glioblastoma in the United States in 2015 and reached at the time of peak market penetration around early 2021. We more recently, starting end of last year and through the first 2 quarters of this year, have returned the business to growth where it was just 8% year-over-year volume growth. And we've done that through a couple of key initiatives.

Number one, first and foremost, we've invested heavily into how we develop patient identification, segmentation and targeting tools. It's -- glioblastoma is thankfully a very rare disease. We are the only branded product in that disease. And so we don't have the luxury of having off-the-shelf tools. We really had to pioneer how do you find GBM patients.

Then the second area that we benefit from is that as we've launched our other products in non-small cell lung cancer and pancreatic cancer, we've effectively doubled our sales team. So we're able now to cover the practices that are high volume for GBM that we've covered for years and expand into the community practices that may only see 1 or 2 GBM patients each year.

Okay. And you expect that growth to sort of continue going forward and into 2027?

We do think that as we get to the end of the year, the comps will begin -- the year-over-year comps will begin to get more challenging. But on an absolute basis, we are committed to continuing to grow GBM as a single-digit growth franchise. To put it in perspective, in the U.S., we think our penetration rate is about 35% to 40% of the eligible patients. And for a product that has shown durable median overall survival, 2-year survival and really good patient tolerance, we don't see any reason why we can't continue to push that for several years.

Okay. I know you've got an ongoing Phase III trial in GBM, that's your KEYNOTE D58 trial. Can you give a quick overview of it? And if successful, what impact you think that could have on the future of this business?

Absolutely. So our current approval in glioblastoma is with what's known as the Stupp protocol. So a patient will be diagnosed with glioblastoma would receive surgery, roughly 90% of the patients receive surgery, followed by chemo radiation with temozolomide and then maintenance temozolomide. Tumor Treating Fields from our clinical data set in EF-14 was added at the time of the maintenance chemotherapy and showed an improvement in survival.

And what we are now studying is, in addition to building off the Stupp protocol is adding pembrolizumab on top of Tumor Treating Fields to see if we can extend survival even further. And we would view this as -- we view this as meaningful in 2 ways. One, any improvement in survival is still needed. Median overall survival is still now hovering around 21 months when patients are treated with Tumor Treating Fields, which is a great improvement, but there's more to be done.

And then the second part of this is that immune checkpoint inhibitors have consistently failed when applied in brain -- in all brain neoplasms and specifically glioblastoma. So we think there's a secondary scientific clinical validation that Tumor Treating Fields does lead to a modulation of the tumor microenvironment, which leads to a better response to immune checkpoint inhibitors. And that's a signal that we've seen in pilot studies, animal studies. We've seen it in our non-small cell lung cancer data. And if we can replicate that in GBM, it's, I think, a tremendous win for us.

That's great. We look forward to it. And sorry, what's the timing of that potential readout?

We are hoping -- we intend to complete enrollment of the trial by the end of this year with an expected readout. It's an event-driven readout, but it would be around 2 years from now.

Okay. You mentioned pancreatic as an important area and an important launch for you. There's been some important developments in the treatment paradigm and the competitive set in pancreatic cancer, specifically RevMed's recent RASONQUE approval in previously treated metastatic pancreatic cancer. So can you give just an overview of the Optune Pax program and kind of how you're thinking about...

[Audio Gap]

Stage III disease, non-resectable as a first-line treatment. RASONQUE is now approved for second-line treatment of metastatic disease, so Stage IV. So these are 2 distinct patient populations. Typically, metastatic patients will present, particularly at second line, with overwhelming physical disabilities, need for urgent treatment -- emergent or urgent treatment. The locally advanced patients are typically presenting with general discomfort but still really good health. And whether they score as resectable or non-resectable, they often start treatment with the goal of getting to a surgery.

And our device in that locally advanced population has the strong data set that indicates we were able to enhance local disease control, delay disease progression to the liver, and extend pain-free survival. So in that locally advanced patient population, we think we have a distinct population.

Now, that being said, first of all, it should be, you know, for patients, this is a huge win now to have RASONQUE on the market. It's clearly an incredibly valuable -- it's an incredibly valuable tool for physicians treating patients with metastatic disease. And we can talk more of some of the things that we're thinking about in terms of how do we integrate with daraxonrasib as it moves into other indications, potentially some of the other new cutting-edge therapies that are coming to market as well.

Okay. You also just mentioned your plans to explore the use of Pax with KRAS inhibitors in the past. Can you tell us kind of the rationale between combining that product with other potential programs that are out there?

Yes, absolutely. It starts with, first and foremost, Tumor Treating Fields across now multiple Phase III trials as well as a huge number of preclinical trials, has always shown the ability to be additive, if not synergistic, when applied with other systemic therapies. And the great advantage of Tumor Treating Fields is that we do not have adverse events on a systemic level. It's really skin irritation has been the primary adverse event. So you have low-to-no toxicity Tumor Treating Fields, not inhibiting the systemic therapy of choice.

And so the question becomes, how do you best optimize both therapies? We've now completed our preclinical research that was then validated by the Mayo Clinic, looking at KRAS inhibition on top of Tumor Treating Fields, and we see really promising preclinical signals to say there's a rationale for bringing these two therapies together. And so we've moved ahead and announced that we will open a trial as soon as feasible where we will pursue a clinical trial with daraxonrasib on its label in metastatic second line with Tumor Treating Fields is being added as the investigational device. And we're going to make sure that we capture the safety and feasibility data to start showing doctors how we use these two therapies together.

Okay. And do you think, I mean, is it more about combining your technology with on-market programs or can you think a little bit earlier about, you know, combining your investigational therapy with another investigational therapy, and how do you think about that combination strategy?

Well, we think -- I'll turn this over to Christoph in just a second, who actually leads our activities in those areas. But for us, we are happy to work with any companies that are willing to work with us and that there's a good clinical rationale.

Yes, and as Frank alluded to, so on the one hand, we are looking at a trial, an IDE trial with daraxonrasib and TTFields and that will be though in their approved indication, second-line metastatic. Now, we are also looking at a trial in our approved indication, locally advanced, first line, and that would be in combination with a not yet approved KRAS agent.

Okay. Makes sense. Makes sense. Can you just give an update, either of you, on the process of launching additional pancreatic cancer trials and kind of where you stand in terms of expanding that opportunity?

Yes, we're actively looking at where do we go next within pancreatic cancer. And I think it's such an evolving landscape right now in terms of the entry of daraxonrasib, RASONQUE, into actual commercial use, different RAS inhibitors, targeted RAS inhibitors. I think we'll have more to say as we go into next year.

At a high level, one of the things that we've challenged our teams to recognize and address is that in these markets where there's emerging therapies coming to trial constantly throughout the year and really having the potential to disrupt the landscape over and over again. We need to be more flexible, nimble, and faster getting to data readouts that can lead to registration versus, I think, historically, when we were a less proven therapy, we had the burden of doing these large drug-like trials trying to get the overall survival. But going forward, I hope that we can find a way to do that in a faster way.

Okay. I think the idea of global expansion of your product is going to be a very important part of the growth story going forward. So I know you've secured CE Mark for Pax, and have also submitted for approval in Japan. So can you talk a little bit about any upcoming European launches, Japanese approval expectations, and kind of how you think about the global opportunity here?

Absolutely. Yes, we're really excited and proud of the fact that NovoCure starting from -- literally starting from being a startup in Israel has now grown into having operating businesses in 16 countries around the world. And that means we have this very diversified business now between GBM, PANC, Lung, and we're excited to launch the Optune Pax device for pancreatic cancer in Europe already, in Germany, where we're able to go case by case in our launch. And then looking ahead, we have said we hope to have approval in Japan by the end of this year with a reimbursement approval sometime in the first half of next year.

So Europe, Germany will go first, then we have to begin working on markets like France where it's more regimented national reimbursement. And so we think, to put it in context, I would think of the pancreatic business in Europe will probably take a year plus to mature and we'll really know where it's going. In Japan, we have national reimbursement. So if we are successful and we believe we will be successful, we go into next year launching -- we would go into the first half of next year launching with national reimbursement in an indication that it has a higher prevalence in Japan than in the United States.

Okay. So it sounds like in Europe it's a little bit more on a country-by-country basis, working through the reimbursement kind of, not challenges, but just working through that operationally.

Absolutely. No. And there are challenges because it is a market where we will have challenges over payment levels. And so we are confident that we can work through those. It's -- but it is -- it can be a long process as we've seen with GBM to really get the European businesses up to stable levels.

Okay. Anything you want to mention just on the lung cancer launch and kind of how you see that going forward?

Yes. We -- so as you know, we launched our non-small cell lung cancer device, Optune Lua, at the end of 2024. It is targeted into second-line Stage IV non-small cell lung cancer. This is a very sick patient population. And in the U.S., unfortunately, our -- the data from our clinical trial was, I would say, scientifically and clinically compelling, but unfortunately, the standard of care shifted. So we've seen real challenges in our U.S. business trying to commercialize and launch. And we are kind of where we are now in terms of the U.S. business.

The flip side, though, is that in Japan, the clinical treatment guidelines are more flexible in terms of continuing an immune checkpoint inhibitor from first line to second line. And so it aligns more closely with the data that we have from our pivotal trial. So at Q2, we were pleased to talk about our success in Japan with the initial launch for non-small cell lung cancer. And we see that continuing, and we feel that's going to be a good tailwind for the business in Japan for years to come.

That's great. Just turning to Christoph for a moment. You've been very vocal about your pursuit of profitability as a company, and you're kind of turning the corner on that. So can you give us a little bit of an update and kind of what are the next benchmarks in your path to profitability and when you expect to reach them?

Yes. So in terms of profitability, we said for us it's a three-step process. Step 1 is to become breakeven on adjusted EBITDA as a proxy for profitability. Step 2 is to become cash flow breakeven, and then step 3 is to become truly breakeven on a net income U.S. GAAP basis.

We are quite happy in terms of where we are this year or the progress that we have been able to make this year, in terms of true enterprise-wide focus on not only growth, but also profitable growth. So as we said in the past, we believe we made the -- largely the investments that we need to go through the launch period and now extract the leverage out of the P&L, meaning revenue growth being higher than expense growth.

And we see the fruits of this, this year with the guidance that we gave at Q2. We said that at a minimum, we believe we will be breakeven on an adjusted EBITDA level by the end of this year, potentially up to $50 million positive adjusted EBITDA. And again, the next step once clearing just the EBITDA breakeven would be to become cash flow breakeven. And that's approximately $30 to $40 million more in terms of profitability that we need for that. We haven't given explicit guidance, but we believe that it's in reach in the foreseeable future.

You guys have clearly done a great job of kind of managing costs. I mean, how do you think about managing that OpEx when you think about global expansion going on, multiple programs reaching later stage trials or enrolling or reading out? Clearly there's a lot you're trying to manage through. So how do you think about kind of controlling that OpEx spend?

Yeah, we believe that we -- I mean, we are very committed to keeping our expenses and expense growth, be very disciplined about it. And even more specific, what we said is that on R&D, to be exact on the specific P&L lines, on R&D we don't expect growth. On G&A, we don't expect growth. I mean, there will be inflation-adjusted growth at most. And sales and marketing, there will be some moderate growth for the launches that we expect.

But again, largely speaking, we have invested in our capabilities in the last couple of years, and we believe that now we have essentially the infrastructure in the 16 countries that we are in to go through this period of launches and internationalization with really only moderate additional investments needed.

Okay. And with $440 million on the balance sheet at the end of the quarter, do you think that your current capital position is adequate to achieve some of these goals without having to go access the capital markets again in the near term?

Yes. So we have -- last time we reported $440 million, roughly speaking, on the balance sheet in terms of cash. That includes $200 million of debt. At the beginning of the year, we made a decision. We had a credit facility that allowed us to go up to $400 million of debt. And we made a decision to basically stay at the $200 million level, because we thought it's more important to now really double down on profitability. And so, yes, we feel comfortable with the balance sheet that we currently have. We also think that debt has a place on our P&L from a pure cost of capital perspective. And we believe we don't need to go to capital markets.

Okay. Frank, another question for you. I know you've served in multiple different roles within the organization over the course of your career. And I'm just thinking about, as you assess the team today globally, how do you think about -- you have the right players on the field to kind of execute against your goals and how you think about the culture of the firm today?

Yes, it's a great -- I'm privileged to answer that question. I really -- it's -- being in this role is really truly humbling because this is a company where you have people who have been here for 25 years, and you have people who have been here for 25 minutes. And you're trying to meld those 2 together into a world-class healthcare company. And I think that's the advantage -- high level, that's the advantage we have is we have people who have been really dedicated, deep science research, deep knowledge of how the technology actually works, and we're now pairing that with bringing in people from outside who have had expertise running global businesses.

And I think, as I think about it, about it, that's our biggest team dynamic challenge that we'll have in the coming year. And -- but I think where this really comes down to, and it dovetails off the question about the balance sheet and capital allocation strategies. We are now in a place where we've earned the right and the privilege to control our own destiny. We, this year, got cost under control. We restarted growth in the businesses. You asked where do we have really outstanding leadership. I would highlight that our business leadership and our medical leadership broadly defined really came together and took a franchise that for 10 years had been in market and got it growing again in every key market. So I think we have really outstanding people here.

And I think what we have to do now is take a step back and on the R&D side say, okay, what does the future of R&D look like at NovoCure? How are we going to conduct clinical trials? How are we going to be the device in these indications where drugs are evolving every year as opposed to every five or 10 years like it used to be. And I think that once we get that strategy articulated both internally and externally, you'll see pretty quick execution because we have the right people.

That's great. And kudos to you guys for, kind of, once you've been in the seat, really taking responsibility around how you guide the street to forward-looking expectations, both from a financial perspective and an operational perspective. I think you guys have done a great job.

Maybe just one final question before we wrap up for you, Frank. What do you think might be misunderstood about the story, and what are you most excited for looking at the next 12 months?

I think that in terms of the story broadly defined, I think that the breadth and diversity of our overall business is sometimes missed because for so long we were a glioblastoma business and we were a glioblastoma business in the U.S. Over the last 2 years, our business in France grew to maturity, our business in Germany after a trough has returned to growth. We've been able to get national reimbursement in Spain. We've put the right structure in place so that our team can execute in these smaller markets. So we've grown GBM outside of the U.S. and in the U.S. And then we've paired that with now a strong early launch in PANC. We acknowledge now we have RASONQUE on the market, and that's going to create some disruption in terms of practices and our ability to get into practices.

But we've seen a good early launch into Q2 and then we've also seen a good launch in non-small cell lung cancer in Japan. So our revenue streams are diversifying, our geographic footprint is diversifying. And then I think to just really put a final statement out there, what I highlight over and over again is that our business in Japan today is the fourth largest business in our portfolio. And that's largely due to the fact that the incidence of GBM is relatively low in Asian populations and specifically in Japan. As we move into these bigger indications of lung cancer and pancreatic cancer where the incidence is either on par or greater than Western populations, Japan has the ability to be that financial driver for the business for more than just 2027.

And so we feel like we have a really strong, durable, stable revenue base. We have good controls now over our operating expenses. And so I think now it's up to us to figure out, okay, then what does this look like, not just over the next 1 year or 2 years, but where do we go from here in terms of maximizing the clinical benefit of Tumor Treating Fields?

That's great. Well, congratulations on all the progress.

Thank you.

And thank you for joining us at the Morgan Stanley Healthcare Conference. Great to have you here.

Thank you very much. Appreciate it. Thanks for having us.

Good day, and welcome to NovoCure's Second Quarter 2026 Earnings Call.

[Operator Instructions]

Please note this call is being recorded. I would now like to turn the call over to Adam Daney, Head of Investor Relations. Please go ahead.

Good morning. And thank you for joining us to review NovoCure's second quarter 2026 performance. I'm joined on the phone today by our Executive Chairman, Bill Doyle; CEO, Frank Leonard; Chief Innovation and Medical Officer, Uri Weinberg; and CFO, Christoph Brackmann. For your reference, slides accompanying this earnings release can be found on our website, www.novocure.com, on the Investor Relations page under Quarterly Results.

Before we start, I would like to remind you that our discussions during this conference call will include forward-looking statements, and actual results could differ materially from those projected in these statements. These statements involve a number of risks and uncertainties, some of which are beyond our control and are described from time to time in our SEC filings. We do not intend to update publicly any forward-looking statement, except as required by law. Where appropriate, we will refer to non-GAAP financial measures to evaluate our business, specifically adjusted EBITDA, a measure of earnings before interest, taxes, depreciation, amortization and share-based compensation.

We believe adjusted EBITDA is an important metric as it removes the impact of earnings attributable to our capital structure, tax rate and material noncash items and best reflects the financial value generated by our business. We do not provide forward-looking guidance for adjusted EBITDA on a GAAP basis due to the inability to predict share-based compensation expenses contained in the reconciled GAAP measure, net income, without reasonable efforts. Reconciliations of non-GAAP to GAAP financial measures are included in our press release, earnings slides and in our Form 10-Q filed with the SEC today.

These materials can also be accessed from the Investor Relations page of our website. Following our prepared remarks this morning, we will open the line for your questions. I will now turn the call over to our Executive Chairman, Bill Doyle.

Thank you, Adam. This morning, we reported our second quarter 2026 results, and I am pleased to say this was our strongest commercial quarter to date. With record net revenues and active patients on therapy, we continue to build on the momentum of the first quarter and have also made meaningful progress on our path to profitability. I will begin this morning with a review of our commercial results.

Frank will then provide an update on our clinical strategy. Christoph will conclude our prepared remarks with a review of our quarterly financial performance before we open the line for questions. All 3 of our approved products contributed to our commercial performance this quarter. Starting with Optune Gio, we finished the quarter with 4,636 active patients on therapy, an increase of 11% year-over-year.

A key driver this quarter was U.S. growth, where active patients increased 8% year-over-year. In recent years, we have implemented a number of strategic and structural changes to our U.S. commercial operations that are now bearing fruit. We also saw double-digit year-over-year growth in Germany, Japan and in our Global Markets group.

We are pleased with the Optune Pax launch to date. We received 418 prescriptions in the quarter and 285 Optune Pax patients were on therapy as of June 30. We have successfully completed our early launch objectives to engage, train and support prescribers who were familiar with Optune Pax from pre-approval clinical presentations of the PANOVA-3 results. We are encouraged by the adoption of Optune Pax at both academic and community practices.

From here, our teams will focus on generating consistent repeat prescriptions and engaging physicians who may be less familiar with the clinical data supporting use of Optune Pax. To close on the U.S. Optune Pax launch, I note that our interactions at this year's ASCO conference confirmed that the PANOVA-3 survival data is viewed as important and relevant for patients with locally advanced pancreatic cancer.

Earlier this month, we received CE Mark for Optune Pax for the treatment of adult patients with locally advanced pancreatic cancer of exocrine origin, concomitant with gemcitabine and nab-paclitaxel in accordance with local guidelines. We have since finalized labeling and registration in Germany and begun certifying prescribers. The reference to local guidelines in our label reflects the fact that nab-paclitaxel is not approved for locally advanced pancreatic cancer at the EU level. Whereas nab-paclitaxel is recommended for use in the country-level clinical guidelines of many European countries.

Turning to Optune Lua. We finished the period with 207 patients on therapy. The early signals from the Japan launch are consistent with our previously stated expectation that clinical practice patterns in Japan align more closely with our label than other Optune Lua markets. As a reminder, we received national reimbursement in March and began certifying physicians soon after.

As of June 30, we had 64 Optune Lua patients on therapy in Japan. We are still in the early phase of the launch in Japan. While the established reimbursement policy covers all Japanese patients, additional contracting is required at each treatment site.

As more hospitals and prescribers are contracted in the coming quarters, we expect Japan to be our leading Optune Lua market. Finally, the FDA review of Optune Maia for the treatment of brain metastases from non-small cell lung cancer remains on track for a Q4 decision. Earlier this month, the NCCN updated guidelines for the treatment of brain metastases and included Optune Maia as a Category 2A recommended treatment option for patients with limited brain metastases from non-small cell lung cancer without targetable mutations.

We are pleased that the NCCN opted to include TTFields therapy and believe this will be helpful for a future launch pending FDA approval. With 3 devices launched and a fourth under FDA review, we are in the favorable position of having multiple products contributing to growth in the coming years. We are focused on achieving the regulatory and market access milestones required to bring Tumor Treating Fields therapy to more cancer patients in more regions as quickly as possible.

Frank will now walk through some of the updates to our clinical programs.

Thank you, Bill. We are entering a new phase of clinical development at NovoCure. Historically, our clinical strategy has focused on areas of significant unmet need and opportunities to establish TTFields in new cancer types. With 3 products approved and under FDA review, we are shifting that mandate to focus on strengthening our market position and broadening labels.

Our near-term focus is pancreatic cancer. Optune Pax is currently approved for first-line use together with gemcitabine and nab-paclitaxel in locally advanced pancreatic cancer, which is classified as Stage III. Our primary goals are to solidify our position in the locally advanced setting and explore TTFields therapy use in earlier stages of the disease where the tumor is or may be resectable. We are designing additional sponsored trials to support label indication in both locally advanced disease and earlier stages of pancreatic cancer.

We are also in active negotiations with industry partners to explore the concomitant use of TTFields therapy with either KRAS inhibitors or other innovative approaches to treat pancreatic cancer in pilot trials focused on feasibility and early efficacy signals. This approach is grounded in extensive discussions with prescribers, key opinion leaders and the preclinical results showing promising signals from the concurrent use of TTFields and KRAS inhibitors.

We believe this focus will best position Optune Pax to remain integral to the evolving standard of care in pancreatic cancer.

In addition, we are preparing to open an IDE trial for concurrent use of TTFields therapy and daraxonrasib following its expected FDA approval. The intent of this trial will be to generate safety and feasibility data quickly and provide physicians with clinical data to evaluate how best to use the 2 therapies moving forward.

We do not intend to open a registrational trial in metastatic pancreatic cancer at this time. We are also continuing our efforts to increase the data supporting use of TTFields in our approved indications for GBM and non-small cell lung cancer. The KEYNOTE D58 trial is on track to complete enrollment by year-end with database lock and top line readout approximately 2 years later.

KEYNOTE D58 is a Phase III trial exploring the addition of pembrolizumab to the current standard of care of TTFields therapy and maintenance chemotherapy for GBM. Turning now to non-small cell lung cancer. LUNAR-2 is a Phase III trial exploring first-line use of TTFields therapy, pembrolizumab and platinum-based chemotherapy for the treatment of metastatic disease. We have initiated several changes to this trial with the goal of lowering total trial costs and accelerating the pace of trial completion.

The first step was the optimization of our clinical footprint. We are in the process of reallocating clinical resources to high engagement, high enrolling sites and discontinuing the trial at lower enrollment sites. The second step is to amend the protocol to streamline the trial's primary endpoints with the goal of reducing the patient sample size.

We believe these changes will cut the total spend on LUNAR by approximately $90 million with the savings allocated to pancreatic cancer programs. The refreshed focus of our clinical program should be beneficial on several fronts. First, it will enable faster data generation, address potential data gaps and provide flexibility to remain ahead of the evolving standards of care.

Second, these changes allow us to balance ongoing R&D investment at our current level with our goal of reaching profitability in the coming years. Finally, I want to express my thanks to all the NovoCure employees for their hard work and dedication to achieving our goals. We have started the launch of Optune Pax, refocused our R&D efforts and implemented operating expense discipline to ensure we have a clear path to profitability.

We made great strides towards these goals in Q2, and I'm incredibly proud of what the team has achieved overall this year. I'll now pass the call to Christoph to review our financial performance in the quarter.

Thank you, Frank, and thank you all for joining us this morning. We continued our strong start to the year in Q2. Net revenue in the second quarter was $184 million, an increase of 16% year-over-year. The increase was driven by Optune Gio active patient growth of 11% year-over-year as well as increased contributions from Optune Lua and Optune Pax of $5.4 million and $1.6 million, respectively.

We benefited from $3 million in onetime items, driven by increased approval rates and aged claims in Germany, lower annual deductible reset impact in the U.S. and performance improvements in France. The exchange rate impact versus Q2 of last year was overall immaterial with some benefits in Europe being offset by the Japanese yen.

Based on the strength of our commercial performance in Q2, we are updating our full year revenue guidance to a range of $710 million to $725 million, representing 8% to 11% growth. We are also updating our guidance range for combined revenue from Optune Lua and Optune Pax to $20 million to $30 million for the year. Gross margin in the quarter was 78% compared to 74% in Q2 of 2025.

This was primarily due to a tariff refund of $5 million as well as lower array costs due to improved utilization and manufacturing efficiencies. We expect quarterly gross margins to remain in the mid-70s through year-end 2026 as we bring more Optune Pax patients on therapy prior to establishing broad reimbursement. Research and development costs in the quarter were $51 million, a decrease of 8% compared to the same period in 2025.

The change was primarily driven by lower direct trial costs associated with Phase III trials that have concluded as well as lower costs associated with the LUNAR-2 trial. With the redesign of our LUNAR-2 trial, we are confident that we can keep R&D costs at or below current levels in the future while being able to invest in our clinical development aspirations as outlined by Frank earlier.

Sales and marketing expenses in Q2 were $62 million, up 8% from Q2 2025. The increase was primarily due to costs associated with the ongoing launch of Optune Pax in the U.S. and Optune Lua in Japan. G&A costs in the quarter were $40 million, a decrease of 9% from the same period last year. This was primarily driven by lower share-based compensation expenses. Our net loss for the quarter was $16 million compared to $40 million in Q2 2025.

Loss per share in the quarter was $0.13. Adjusted EBITDA in the quarter was $11 million compared to negative $10 million in the second quarter of 2025. We are updating our full year adjusted EBITDA guidance this morning to a range from $0 million to $15 million. Our cash and investment balance as of June 30, 2026, was $441 million. We are unambiguous in our enterprise-wide focus on reaching profitability in the coming years.

This includes driving strong revenue growth as well as diligent expense management and the pursuit of cost optimizing projects like the LUNAR-2 trial. In recent years, we have made the infrastructure investments required to support the commercial operations of Optune Gio, Lua, Pax, and Maia. As these launches continue to gain momentum and net revenue continues to grow, we expect to see significantly greater leverage across the P&L, providing a tailwind to profitability.

The first milestone in our path to profitability is to reach breakeven on an adjusted EBITDA level, which we now plan to achieve for the full year of 2026. Thank you all for joining us this morning. We'll now open the line for Q&A.

[Operator Instructions]

Our first question comes from the line of Vijay Kumar with Evercore.

Congrats on a nice print here. Maybe my first one on this pancreatic launch. Script volumes up sequentially in the triple digits, active patients up north of 200%. I guess, can you give us a little bit more flavor on where is this growth coming from? How many docs are prescribing currently?

Is this coming from existing physicians or new physician adds? And when you think about that sequential trajectory, it looks really strong. Is this sustainable here for back half? Like how should we think about Pax launch, continued adoption, if you will, for the back half?

Vijay, thank you. This is Frank. I appreciate the question, and we'll start by noting that we are pleased with the launch in pancreatic cancer. As a reminder, for Q1, we really only had 1 month of activity.

So in looking from Q1 to Q2 on pure statistics, it is absolutely a strong quarter in terms of statistical growth. But to give it the color and the context that you asked about, I would say that we have been, first and foremost, very pleased with our ability to interact both at community practices as well as academic practices. And so in terms of the sites that we're training and certifying, we're seeing that breadth across different types of providers.

We are not giving context right now on the total number of certifications, but I would say that from a color perspective, we've been able to get access to the practices and to ensure that we can get certifications done quickly. We are right now looking at about half of our prescriber base has already become a repeat prescriber with the other half having initiated treatment once. And we think that at this point in the launch is pretty common.

We have a big set of physicians who are interested. And as with any new modality, there's that interest to get it on one patient to try. And then the challenge for us as we move forward to answer the part of the question about the future, as we look ahead, one of our major focuses for Q2 -- Q3, pardon me, is that we need to push that number of repeat prescribers up and go from trying Optune to Optune is integrated in my practice.

That's helpful, Frank. And then maybe one more on Pax. I think I heard you say you'll start an IDE trial for TTF plus RAS inhibitors. I'm curious, when you look at these early data that you have and when you compare to early data that you had in other indications, right, like what gives you the confidence here on TTF plus RAS?

We're seeing a positive signal that gives you the confidence to start this IDE trial. And I think I've heard you mention this is going to be an IDE, but not a registrational study, right? Like why is this an IDE, not a registrational trial? And at some point in the future? Do we need a registrational study for TTF plus RAS?

Yes. Thank you. Yes. So to highlight our -- what we've announced in this call is that we do see interest and, in fact, a need to open a trial where physicians can use TTFields plus a RAS inhibitor. The fastest way to do that is after daraxonrasib has its FDA approval, we can do that through an IDE trial.

As you noted and as I'll reemphasize, we are opening this trial in order to look at safety and feasibility signals as these are both 2 new modalities. And we are really looking at it from that perspective of safety and feasibility. And we are not in metastatic disease looking to move towards a registrational trial or indeed to a larger trial with hard efficacy endpoints.

I'll let Uri speak in just a moment to some of the preclinical rationale. But what I will say is that as we spend time at ASCO and in fact, as we've interacted with our prescribers, we do just see the clinical interest in answering the question of how can you use these 2 therapies together. And so we believe we need to work as fast as possible to begin addressing that question. Uri?

So from a scientific perspective, we have been able to publish already that TTFields therapy in the preclinical setting led to the downregulation of c-Myc, which is a master regulator of cancer cell proliferation and metastasis. And c-Myc being downstream of RAS in many cases, has the possibility of influencing the overall silencing of this pathway, leading when using TTFields therapy concomitantly with KRAS inhibitors to an overall greater and maybe even synergistic effect. And this has been reported through our preclinical results and has actually been reproduced also by Mayo Clinic and an independent research that was conducted by their research team.

These findings were published in the recent AACR conference. Now on top of the opportunity to get the clinical data as soon as possible by utilizing and using the fact that KRAS inhibitors are primarily going to be approved in metastatic disease first, this also secures and promotes our communication and advancement towards partnerships with other commercial companies in this field, and we are working in this direction, too.

Our next question comes from the line of Jason Bednar with Piper Sandler.

Congrats on another nice quarter here.

I also wanted to start on the pancreatic indication like Vijay. Frank, can you talk a bit more about prescribing patterns, patient acceptance and conversion from Rx to active patients and particularly on that Rx conversion to active patients, are we at a point where we can begin to use the experience thus far to inform how we think about the model and future conversion?

Thank you, Jason. In terms of the prescriber patterns, as I mentioned earlier, we -- right now, we are seeing about 50-50 of prescribers who have tried it once and those who are going to -- who have used it multiple times. We expect over the coming quarter to continue broadening out the number of prescribers, but we will focus in this quarter on driving up the repeat prescribers because it's -- if you think about the effort on our side and the effort on the physician side to use the therapy for the first time, once you've cleared that hurdle, it's really a time to consolidate the engagement with the practice and drive up the volume.

And I say that because as I looked at our prescribing patterns for this quarter, one thing that does jump out is that we have -- in terms of our highest volume sites, for the first time, it's both a mix of community and academic practices. whereas I think as you know, in the past, we've sometimes had challenges getting into these large academic practices. We're not seeing that this time around either.

So to sum up on prescribing patterns, I think it was a good effort in the first 2 quarters of the launch to get to the physicians who are interested. It was a good effort to get as many people prescribing as possible. We're seeing repeat prescribing in 50% of the population, and we're seeing access to academic sites in a way that we haven't seen before. In terms of modeling fill rate or conversion rate from Rx to start, I would say because it's a launch and because it was the first full quarter, I wouldn't begin trying to glean specific statistics from the numbers. I think you'll need a little bit more time from a sample size perspective.

Okay. All right. Maybe one follow-up, and then I've got one for Christoph, too here. I'll just pack them both together. But on the fill rate conversion rate, is there a reason to think Pax is different from Gio longer term?

Just anything structurally or about that indication that you think we should be using or assuming different fill rates? And then Christoph, the business is definitely establishing a better revenue execution pattern here, another guidance raise second of the year.

I guess the question, though, even with the raise, the high end of the revenue guide implies a growth decel in absolute revenue that's on par with what you just put up in 2Q. So maybe help me why is that the right level? It seems like we should be even higher than where you took things.

Jason, on the fill rate question, I think I don't think I would draw a direct connection to GBM or a reference point yet. The patient population just based on the chemo regimens, it's -- we really do -- I think even we would say this to ourselves, we need a little bit more time to really see where the fill rate settles.

What I would say, though, is that it's a shorter time between prescription and start than what we typically see in GBM, and we do see really motivated patients. So I wouldn't -- I don't want to draw a conclusion one way or the other, but I also don't -- I don't want to raise any alarms that we think it's going to be very low, I guess, is what I would say.

Okay. And thank you, Jason, for the revenue question. So maybe first as background, we increased the net revenue guidance from $690 million to $710 million to today $710 million to $725 million, which would be a range of 8% to 11% in growth and the midpoint is double-digit growth, 10% growth.

So we're very happy based on the strong performance in Q2 to be able to, what I would call, substantially raise our revenue guidance. Now with regards to your point on the high end of the revenue guidance is basically in line with the Q2 results.

Two answers. So one is -- we called out $3 million in onetime items in Q2. And the other one is, I would say, Q2 was really an exceptional quarter where we had sales of $10 million more than in the prior quarter or $9 million if we compare to Q4.

So really, we would say the stars aligned in Q2, particularly also with having a very strong growth in the U.S., 8% year-over-year active patient growth in the U.S., and you know that, that has a fairly substantial impact on revenue. So long story short, we are very focused to achieve an outcome that is towards the higher end of our guidance range, but we also wanted to respect that we had a fantastic quarter in Q2.

Our next question comes from the line of Larry Biegelsen with Wells Fargo.

Congrats on a nice quarter. So I wanted to ask about Lua in Japan, which was strong in the second quarter. Was there a pent-up demand? And how should we think about that going forward? It does look like when I -- Christoph, when I look at the guidance for Lua and Pax, it almost seems to imply Lua revenues flat in the second half of the year if Pax is growing. And I have one follow-up.

Yes. So maybe first on Lua in Japan in general. We are very pleased with the launch, and we had the hypothesis that our data from LUNAR overlaps better with the standard of care in Japan than in other markets, and that I think has proven to be the case. Now we do expect sequential increase in patients. I would say, in particular with Lua, the duration in the clinical trial was about 4 months.

So growth will, at some point, get more difficult, but we do expect sequential growth. And with the revenue guidance, I would just say for the new products, it's very difficult to project. And yes, we -- maybe the other point for Japan specifically is -- we have national reimbursement, but we have to work through a contracting process hospital by hospital. And while we do make significant and have made significant progress in Q2, that's a gating item, and it's just something that the team will need to continue to work through.

That's helpful. And then maybe, Frank, back to Optune Pax. Once the RAS inhibitors are approved, which is expected shortly, do you think they'll be used off-label in earlier stages of pancreatic cancer? And what are clinicians telling you about their willingness to prescribe both the RAS inhibitor and TTF in the same patient before you complete this IDE you talked about today?

Thanks, Larry. Yes. I mean, I think just as a company that's committed to innovation, I'll start by noting that we're very happy that there's going to be another therapy approved for pancreatic cancer patients. Even with the success of daraxonrasib, we're still talking about median overall survival of approximately 13 months in their indication. And so we think there's still more to be done.

And as with all of our indications, we think that Tumor Treating Fields is particularly capable of being a backbone therapy as new medical therapies come to market due to our low toxicity profile, nonsystemic toxicity. Specifically, what we're hearing from our KOLs and our prescribers is that there is an interest in understanding how to use Tumor Treating Fields with RAS inhibitors. I'll note, as you know, Larry, we are approved in locally advanced pancreatic cancer, and they will be coming to market in second-line Stage IV, so later stage and in the second line of treatment. And I think it's too early to predict an exact impact of what will happen in the real world because there's payer dynamics that will be at play, too, in addition to clinical dynamics of how RAS inhibitors are introduced.

But I think we're very confident based on everything we've heard to date that within locally advanced pancreatic cancer, our indication that there's strong interest in Tumor Treating Fields and whether it's RAS inhibitors or new agents, we'll have to continue studying Tumor Treating Fields with them and building that evidence for clinicians.

Our next question comes from the line of Jess Fye with JPMorgan.

Another one on Optune Pax. I was trying to infer from your comments about the mix of onetime prescribers versus repeat prescribers so far, but figured maybe just to ask you directly, like what's the total number of prescribers who are sourcing those 418 Pax scripts in the quarter?

Thanks, Jess. We haven't given the specific number of certified prescribers. And we think we've talked about whether or not to give that number. There's some nuances there because it's a different -- not all prescribers are the same. Some are super high volume, some are a doc who mostly does lung cancer, but occasionally does pancreatic cancer.

But what I can say is that the range of prescriptions within a practice right now ranges between 1. They've tried it once and some practices have written more than -- some doctors have written more than 10 prescriptions. And that's really why when we look at this 50% of prescribers who have only written 1 prescription, we see tremendous room for growth if we can drive them to that higher end, that point at which Tumor Treating Fields, Optune Pax is really integrated into their routine clinical practice.

Our next question comes from the line of Kevin DeGeeter with Ladenburg Thalmann.

I'll just add another one on Pax. Can you talk a little bit about the go-to-market strategy in Germany and just kind of how we should think about the dynamics there for initial uptake and payment and reimbursement?

Thank you, Kevin. Yes, I'll comment at a high level about the launch in Germany, and then I'll turn it over to Christoph to talk about our expectations. So Germany, much like the United States, allows for case-by-case reimbursement as new products come to market. And so much as we did in GBM, we are launching the product and then pursuing reimbursement on a case-by-case basis.

We we are typically in Germany, what we're going to do is focus on the large national cancer centers. We are rolling out right now already our initial marketing and sales campaigns and really working on that effort to educate the largest cancer centers and begin certifying them. And then from there, we would expect there will be a build. I think I would highlight that in Germany, we did not have as many of the direct KOLs involved in the trial.

And so there is a bit of an education process that we will have to undertake. But much like in the United States, we've seen a belief in the data that our data from the PANOVA trial was compelling, is clinically relevant. And so we're excited for the launch, and we just have to now work through those reimbursement hurdles.

Yes. And maybe just some words on the total TAM. So incident rates in Western Europe are quite comparable to the U.S. The TAM in the U.S. on label is 15,000 patients annually. And in Germany, it's about 1/4. We expect it to be 4,000 patients on label. And as Frank said, we believe that the build will be at a slightly slower slope than in the U.S., but we're very excited to launch, and we have started to do so.

Our next question comes from the line of Emily Bodnar with H.C. Wainwright.

Congrats on the positive quarter. Maybe also on Optune Pax, if you can kind of discuss some of the early trends you're seeing maybe in the initial patients that are getting on therapy and also any feedback you're getting on prescribers with real-world use of the drug -- sorry, of the therapy?

And maybe for a second, you mentioned the combo TTFields plus RAS inhibitors. It sounds like you're looking at mainly the metastatic setting. I was curious if maybe you could also expand this into the locally advanced setting where you're already marketing.

Thank you, Emily. I'll start with the second half of the question to just highlight that we -- in our work to open trials with RAS inhibitors, there's 2 separate activities underway. One is an IDE trial focused on safety and feasibility.

And that would be a trial run after daraxonrasib has FDA approval to enable us to do a trial with an FDA-approved drug. That would be within their label of second-line metastatic so that we can run that trial as an IDE trial and be the sponsor. It's just the fastest way for us to gain access to the compound once it's approved.

We are also, at the same time, pursuing business development discussions with industry partners to explore earlier-stage trials with both RAS inhibitors and some of the newer more innovative compounds that are being tested in pancreatic cancer. So it is a both story. It's getting data with daraxonrasib as fast as possible and also looking at how we bring these innovative agents along with Tumor Treating Fields to locally advanced pancreatic cancer and earlier stages.

And in terms of your question about some initial stories, feedback, I think there's a couple of -- kind of 2 stories I would share. I think one is we've been pleased with our ability to help a wide range of patients in terms of their physical capabilities and the concurrent therapies they may be receiving. What we've learned through this process is that not all pancreatic patients are the same.

There's varying levels of disability from the disease, of fatigue from the concurrent therapies. And I think what I'm particularly proud of is that our team has figured out how to help all of those patients, keep them on therapy and keep them progressing. And the second thing I would say, I'm talking with several of our KOLs, including one of our top prescribers very recently, we know from the PANOVA trial that pain-free survival extended by 6 months for our patients. And we are hearing anecdotes from the physicians who are hearing it directly from the patients that there is an experience of pain-free survival that there is something happening that's beyond our ability from the data.

We know we can extend overall survival, but we're, for the first time, starting to hear these stories from patients back to their physicians that they can actually feel the pain differently and it gives us confidence that we're pulling through that, that 6-month observed pain-free survival from the trial is, in fact, actually having clinical relevance.

Ladies and gentlemen, I'm showing no further questions in the queue. I would now like to turn the call back over to Frank Leonard, Chief Executive Officer, for closing remarks.

Thank you. Q2 was an exciting quarter for NovoCure. We reached new heights in both active patients and net revenues. We saw another strong quarter of growth in Optune Gio, an exciting introduction of Optune Lua in Japan and continued the promising launch of Optune Pax in the U.S.

In addition to the positive commercial momentum, we have also made significant progress to our objective of returning to profitability, posting a positive adjusted EBITDA result for the first time since 2024. It's truly an exciting time for NovoCure as we bring the promise of Tumor Treating Fields to the more than 5,000 patients on therapy today.

To the NovoCure team, thank you for your extraordinary work this year to help so many patients. We look forward to updating everyone on our progress through the remainder of the year. Thank you for joining us this morning.

Ladies and gentlemen, that concludes today's conference call. Thank you for your participation. You may now disconnect.

Good day, and thank you for standing by. Welcome to the NovoCure's Q1 2026 Earnings Call. [Operator Instructions] Please be advised that today's conference is being recorded.

I would now like to hand the conference over to your first speaker today, Adam Daney. Please go ahead.

Good morning, and thank you for joining us to review NovoCure's First Quarter 2026 financial performance. I'm joined on the phone today with our Executive Chairman, Bill Doyle; CEO, Frank Leonard; Chief Innovation and Medical Officer, Uri Weinberg; and CFO, Christoph Brackmann. Other members of our executive leadership team will be available for Q&A. For your reference, slides accompanying this earnings release can be found on our website, novacure.com on the Investor Relations page under quarterly reports.

Before we start, I would like to remind you that our discussions during this conference call will include forward-looking statements, and actual results could differ materially from those projected in these statements. These statements involve a number of risks and uncertainties, some of which are beyond our control and are described from time to time in our SEC filings. We do not intend to update publicly any forward-looking statements, except as required by law.

Where appropriate, we will refer to non-GAAP financial measures to evaluate our business, specifically adjusted EBITDA, a measure of earnings before interest, taxes, depreciation, amortization and share-based compensation. We believe adjusted EBITDA is an important metric as it removes the impact of earnings attributable to our capital structure, tax rate and material noncash items, and thus reflects the financial value generated by our business. We do not provide forward-looking guidance for adjusted EBITDA on a GAAP basis due to the inability to predict share-based compensation expenses contained in the reconciled GAAP measure net income without reasonable efforts.

Reconciliations of non-GAAP to GAAP financial measures are included in the press release, earnings slides and our Form 10-Q filed with the SEC today. These materials can all be accessed from the Investor Relations page on our website. Following our prepared remarks, we will open the line for your questions.

I will now turn the call over to our Executive Chairman, Bill Doyle.

Thank you, Adam. This morning, we reported results for the first quarter of 2026, and I am pleased to say we've had a strong start to the year. Both active patients and net revenues grew with double-digit rates year-over-year. Our launch in pancreatic cancer is off to a promising start and we are making progress on our journey to profitability.

With a number of additional catalysts expected this year, we look forward to building on this strong first quarter. On today's call, we will begin with a review of our pancreatic cancer program. Frank will then provide an update on our GBM and lung cancer programs. Christoph will conclude with a review of our first quarter financial performance before we open the line for questions.

The leading news in the quarter was the FDA approval and subsequent U.S. launch of Optune Pax for patients with locally advanced pancreatic cancer. Physician feedback has been positive since the PANOVA 3 data were presented and published at ASCO last year. There is broad recognition of the importance of the outcomes observed, including extensions and overall survival and time to pain progression. We believe Optune Pax can play a significant role in the treatment of pancreatic cancer, and we are pleased to be bringing Optune Pax to pancreatic cancer patients.

The early days of our Optune Pax's commercial launch have been encouraging. We received FDA approval on February 11. In the 7 weeks between the approval and quarter end, we certified 868 health care providers, 27 of whom are prescribers and academic centers, an exciting development as historically we've seen slower adoption of TTFields therapy in academic centers. Through March 31, we've received 169 prescriptions and completed 90 patient starts. We ended the quarter with 83 patients on therapy and a backlog of starts in the funnel.

We are also pleased to report our first major payer coverage policy for Optune Pax with Elevance Health, covering over 30 million lives. We will take a few quarters to fully understand the Optune Pax's adoption curve and reimbursement dynamics. But again, the early signals are very encouraging.

During the quarter, we also announced top line data from the Phase II PANOVA-4 trial, evaluating TTFields therapy together with atezolizumab and gem/Abraxane in metastatic pancreatic cancer. PANOVA-4 met its primary endpoint with a disease control rate of 74% compared to 48% in the historical control. Median duration of therapy was 25.6 weeks, a strong indication that TTFields therapy is feasible for use in the metastatic population.

As the pancreatic cancer treatment landscape evolves, we will evolve with it. After years of limited clinical success in pancreatic cancer, the medical community has seen positive outcomes in the PANOVA-3 and PANOVA-4 trials and positive data from a trial testing the pan-RAS inhibitor Draxton Rasib in second-line metastatic pancreatic cancer. RAS inhibitors are likely to be an important backbone therapy in pancreatic cancer in the future, and we are working to understand the benefits of their concomitant use with Tumor Treating Fields.

Earlier this month, at the American Association of Cancer Research, or AACR Annual Congress, 2 posters were presented, which evaluated in vitro and in vivo use of TTFields with daraxonerasid in pancreatic cancer models. The data presented show that KRAS inhibition, which blocks upstream oncogenic signaling and the down regulation of the CMIC protein caused by TTFields produce greater antitumor activity when used together compared to either therapy used alone. These data are promising, warrant clinical investigation and will be important inputs as we consider the next steps in our pancreatic cancer program.

Finally, a quick update on our product development initiatives. Over the last year, we've launched a number of product enhancements aimed at making TTFields therapy easier for patients and prescribers. This includes an HCP portal, which simplifies the prescription process lighter, more flexible, more comfortable HSV arrays for Optune Gio, a mobile app to help patients and caregivers navigate their TT fields experience. We are starting to see the fruits of these enhancements in our 90-day persistent rate, which covered below 70% as recently as 2024. In 2025, we have seen quarterly persistent rates tick up to 73%.

Our next major product improvement will be a new array for the torso. We are now finalizing the design, which will be compatible with Optune Pax and Optune Lua. The new arrays are designed to make major improvements in comfort and usability. We also expect these arrays to be more cost-effective to manufacture. We have completed usability testing in healthy volunteers and are evaluating performance in non-small cell lung cancer patients. Our next game is to have the new arrays available for use in future pancreatic and lung cancer clinical trials by year-end.

I'll now pass the call over to Frank for an update on our GBM and lung cancer programs.

Thank you, Bill. Our Optune Gio business remains the core driver of our commercial portfolio. We are off to a strong start to the year with 9% year-over-year growth in active patients globally. We saw our strongest growth in Japan, Germany and France, which contributed 20%, 12% and 9% year-over-year active patient growth, respectively.

Our Global Markets segment also had an outstanding quarter with 17% active patient growth, driven by a promising launch in Spain. We believe we can maintain low to mid-single-digit active patient growth in our mature markets and even higher growth in new markets like Spain and Czechia.

The next major catalyst in our GBM program will be top line data from the Phase III TRIDENT trial expected in the second quarter. The TRIDENT results will provide us with a better understanding of how TTFields can work with radiation therapy. TRIDENT moves the start of Optune Gio earlier in the GBM treatment journey, beginning with chemoradiation rather than following chemoradiation.

In TRIDENT, the patient population eligible for inclusion is broader than our EF-14 trial. In the EF-14 trial, patients who progressed in the short time between chemoradiation and screening were not eligible for randomization. In the TRIDENT trial, where randomization occurs prior to the start of chemo radiation, we are able to assess the use of TTFields in this previously ineligible cohort. We expect TRIDENT to give further insight into whether earlier use of TTFields therapy can drive additional survival benefit to a broader population of eligible patients.

Turning now to Optune Lua. In March, we received national reimbursement in Japan and began treating commercial patients. Japan provides a promising market for Optune Lua as our LUNAR clinical trial data more closely reflect the standard of care in Japan. On March 15, we hosted a symposium with approximately 250 Japanese lung cancer physicians in attendance, including a number of leading key opinion leaders. We are in the early stages of our launch, but we're encouraged by the physician interest and engagement thus far.

On the clinical trial front, as I have said from the beginning of my tenure as CEO, we need to update our strategy for the LUNAR-2 trial. We are exploring options now to modify the trial with the goals of compressing the time line to completion and significantly reducing the cost. We look forward to engaging with regulators to discuss the potential changes and providing a full update later this year.

Overall, this was a very strong quarter, and we are pleased with our progress. Our commercial focus is on expanding adoption in GBM, maintaining the momentum of our Optune Pax launch and capturing value in the markets where Optune Lua potential is greatest. We've reached a number of exciting commercial and clinical milestones in the first quarter and look forward to sharing more information on additional catalysts throughout the year. Christoph will now walk through our financial results from Q1.

Thank you, Frank, and thank you all for joining us this morning. We had a strong start to the year, continuing our momentum from 2025. Net revenue in the first quarter was $174 million, an increase of 12% year-over-year. The increase was driven primarily by continued growth in our markets outside the U.S. including increases of $6 million and $5 million from Germany and France, respectively. Germany benefited from increased approval rates, which provided a onetime benefit of $2.5 million and France benefited from contract performance improvement, which provided a onetime benefit of $1 million.

We also had a $5.6 million tailwind from changes in foreign exchange rates compared to Q1 2025. Net revenue from Optune Lua in the first quarter was $3 million compared to $1.5 million in Q1 2025. Based on the strength of our first quarter results in GBM, we are updating our full year revenue guidance to a range of $690 million to $710 million, representing 5% to 8% growth. We are maintaining the range for combined revenue from Optune Lua and Optune Pax at $15 million to $25 million for the year.

Gross margin in the quarter was 78% compared to 75% in Q1 of 2025. This was primarily driven by lower costs for arrays resulting from improved array utilization and lower supplier prices. We continue to expect annual gross margin in the mid-70s for the full year 2026, as we bring more Optune Pax patients on therapy prior to establishing broad reimbursement.

Research and development costs in the quarter were $58 million, an increase of 8% compared to the same period in 2025. This was primarily driven by increased costs associated with the KEYNOTE-D58 trial. As a reminder, this is a 700-plus patient trial, which we expect to fully involve by the end of this year.

Sales and marketing expenses in Q1 were $58 million, up 5% from Q1 2025. This was driven by launch costs for Optune Pax in the U.S. and Optune Lua in Japan. G&A costs in the quarter were $86 million, up 92% from the same period last year. As we mentioned last quarter, we incurred a $43 million share-based compensation charge triggered by the approval of Optune Pax. I do want to note this expense is included for GAAP accounting purposes and the grant associated with this charge did not vest and shares were not distributed.

Our net loss for the quarter was $71 million compared to $34 million in Q1 2025. Excluding the onetime share-based compensation expense, net loss was $28 million. Loss per share in the quarter was negative $0.62.

Adjusted EBITDA in the quarter was negative $0.3 million compared to negative $5 million in the first quarter of 2025. We are updating our full year adjusted EBITDA guidance this morning to a range from negative $15 million to breakeven. This reflects our strong start to the year as well as accelerated expenses from our Optune Pax launch.

Our cash and investment balance as of March 31, 2026, was $432 million.

Thank you all for joining us this morning. We will now open the line for Q&A.

[Operator Instructions] And our first question will come from Jonathan Chang of Leerink Partners.

Can you provide any more color on the early Optune Pax's launch like, the number of prescribers, the types of centers where you're seeing utilization, the early clinician patient feedback? And help us contextualize how does this compare to the early lung cancer launch experience?

Thanks, Jonathan. I appreciate the question. We are seeing -- we're really proud of the Optune Pax's launch, both our preparation and also the response from the market. As Bill mentioned in his opening remarks, we had over 800 certified prescribers in just the opening months essentially of approval. And as Bill mentioned, 27% of the certified prescribers are from academic centers. So -- and while we haven't given specific statistics on the number of prescribers who actually wrote in the first quarter, I will say that we were pleased it was a breadth across both community and academic centers as well as prescribers who even in the first 5 weeks wrote multiple prescriptions.

So I think as we get into the second quarter, we will be able to give a little bit more color on that, quantitative color on the prescribing trends and who's prescribing and where. But in terms of just the aggregate demand experienced in the first month of launch, we're very pleased.

And to your question about how this compares to our lung launch, we would say this is across whatever metric we want to look at, it is multiples of demand and really just a significantly different reception from the prescribing community.

And our next question will be coming from the line of Jason Bednar of Piper Sandler.

Congrats on a really nice quarter here, and let's start with Optune Pax. So I'll start there. The launch here is significantly better than what we were thinking. It's really nice to see. Wondering if you could expand a bit more on those results, where you're at with physician on forwarding versus the prescribing process? And I guess what I mean there is your early metrics are so strong and have been wondering about the steps that's converting certified prescribers and 2 active prescribers, are those prescribers predominantly those that were part of your trial and that's why they were able to move so quickly with prescriptions? Just any color you can add here as we think about the launch curve after physicians are certified and then moving into that prescribing of Pax.

Jason, thank you. I appreciate the question. I -- what I would say is the -- to your question sort of around who are those initial prescribers, I would actually start by just referencing back to the fact that this is the first significant approval for this indication. It's really -- if we look just to the stage of locally advanced pancreatic cancer, this is the first successful trial in that space. And so while we've seen very strong engagement from the PIs who participated in the trial, the interest is much broader. And it was essentially a buildup of demand that we were able to meet at centers we've never worked with before, academic centers where we've previously had very difficult times gaining access, wanted to have us in there in the first week so that they could immediately add to the standard of care.

So I think we'll really go into some more numbers as we move forward into the next quarters. But it's -- again, I would say this is very broad-based. There's not one single cohort that was able to go first. And more on that process to remind everyone, as a device, we do have to train and certify our physicians as a first step. Once that training and certification takes place, they're able to prescribe right away. Those who have worked with us before might be a little bit more sophisticated about how to transfer prescriptions to us.

But what I'm also really pleased to say is we've made significant investments over the last year into our HCP portal, the ways in which we work with physicians to transfer the prescription and the related data that's required, such that I think we've lowered the bar in terms of the burden on the physician. And as a result, we've seen that speed to prescribe.

Yes. And the only thing I'd add is, the enthusiasm really started to build at ASCO last year when the data were first presented. We saw just a great reception from the podium. And so to your specific question, the interest has certainly had an opportunity to build and was far broader than the investigators.

Okay. Excellent. Maybe 1 quick follow-up and then a separate 1 on guidance. But a quick follow-up. Just as we think about that launch curve, you've been in market here for now 3 months or almost 3 months, what does that look like in February to March to April, if you can share any real-time feedback on that launch trajectory?

And then separately on the guidance question, for revenue, you bumped the midpoint by $10 million. You beat consensus by $6 million. So a pretty strong statement out of the gate here. Maybe talk about, if you could, what you're seeing real time over the balance of the year that let be comfortable raising the revenue guide by more than the beat?

Jason, I'll comment on the trajectory and then pass to Christopher-- to Christoph. We can't comment on the trajectory in the current quarter only on the prior quarter. I would just say that when you look at the -- there's FDA approval, then there's a bit of time where we have to refile our labeling with the FDA. And you look at the last quarter really in the context of essentially 4 weeks in market. I'd go back to what I said before that we were very pleased by the results. We see real strength in that initial interaction with our customers, and we are very excited for the rest of the year in terms of continuing the momentum. Yes.

And Jason, Christoph here. So to your guidance question, I would say we came off the back of a very strong 2025 and also Q4. And we have seen in Q1 that we were able to carry that momentum into 2026, which gave us the confidence combined with the strong revenue also in Q1 to increase the guidance to what we have seen $690 million to $710 million.

And our next question will be coming from Kevin DeGeeter of Ladenburg Thalmann.

Congratulations on the great quarter. [indiscernible] specifically, can you comment on kind of what you're seeing in terms of your funnel for contracting and coverage with some of the commercial payers and provide any updated thoughts on engagement and potential for CMS coverage for uses for occupant?

Sorry, Kevin, I think we were getting a little bit of a breakup as you were speaking. But I believe the question was directed towards our pathway to coverage and reimbursement for Optune Pax in the United States. I'll start by highlighting we're very pleased to have our first major payer in the United States covering Optune Pax with the coverage policies from -- and we will continue to work through the reimbursement process with the other major payers, private payers in the U.S.

What we've typically said is that we expect around a year to 2 years to work through a coverage process in the U.S. for private payers and more on that full 2-year window to have a revision to the LCD for the Medicare coverage.

In terms of contracting, we had existing contracts in place with most payers in the United States. So we actually do not have a contracting step on Pax. So once a coverage policy is issued the reimbursement is in place on the private side.

Lastly, I'll just close by noting we do have a -- we do view NCCN guideline inclusion as an important step, and we are continuing to -- we have filed with the NCCN to request that guideline inclusion, and we are monitoring the situation closely.

And our next question will be coming from the line of Vijay Kumar of Evercore ISI.

Congrats on the nice print here. I guess, Bill or Frank, my first one was on this pancreatic noted RAS inhibitors. I'm curious on -- just to be clear, right, I think Revolution Medicine had some good data. Just to be very clear, their approval is not a headwind to your -- to Pax, correct? Because correct me if I'm wrong, the indications for your trial are very different versus Revolution Medicine. Could you just clarify that, please?

Thank you. Vijay, thank you very much. Thank you for the question. We are -- when we think about Optune Pax and TTFields for pancreatic cancer, I always want to highlight back to the fact that pancreatic tumors have a low bioavailability for drugs, which is a big reason for why so many drugs have failed in this indication in clinical trials. It's also a reason why we see that excitement from the treating community because using a physical modality against the tumor is intuitive when the tumor has low bioavailability. And so we see this strength of interest in Optune Pax that you see in the commercial launch numbers. But we also do see that in clinical interest in the number of IST proposals we receive and the interest in helping us to design our next wave of trials in pancreatic cancer.

And so we think our device has a unique biophysical rationale for being used in this tumor type that is definitely recognized by the treating community.

In addition, as you know, we are approved for locally advanced pancreatic cancer, which is a unique indication from where the current RAS inhibitor Phase III data is. And we think we feel very confident that we have a path forward to continue the excitement that we've seen in the first quarter. And I'll ask my colleague, Dr. Uri Weinberg, to comment also on the exciting work that we've been doing to study TTFields with RAS inhibitors.

Thank you. Vijay, nice to hear you. So first, we certainly continue to monitor developments in all of our areas of interest, and we are encouraged to see the new advancements in the field of KRAS inhibition, first and foremost, for the patients, but also with a direct relation to TTFields. TTFields were found to inhibit CIMIC, which is a master regulator of cancer cell proliferation. And therefore, TTFields mediation of downregulation of CIMIC may actually complement the upstream KRAS inhibition and that would support a potentially more effective therapeutic strategy when the 2 treatments are used together.

And in particular, CIMIC can also be activated through bypass pathways. And as Bill mentioned in his opening remarks, this data has been recently presented at AACR and in a very complementary fashion an independent group of researchers from Mayo Clinic looked into the concomitant use of TTFields and KRAS inhibitors and also repeated these same preclinical effects and reported even a synergy when the 2 therapies were used concomitantly. So we are very encouraged by that.

Yes. And if we take a step back, we've always maintained that with Tumor Treating Fields, there's an opportunity to use with whatever the prevailing pharmacological therapy may be. We've never seen anything less than additivity. And in certain circumstances, we see the synergy. And now we've seen synergy with checkpoint inhibitors, and we're pursuing that strategy with our KEYNOTE-D58 trial in newly diagnosed GBM. And we can see a future here where synergy with RAS inhibitors is also a very interesting treatment strategy for these very difficult to cure cancers.

That's helpful. And then maybe one big picture question. Look, when I look at the stock, clearly, you're not getting any benefit or credit for some of the positive data you've had, whether it's lung or pancreatic. I'm curious, maybe The Street wants to see revenue acceleration rate. When I look at your assumptions here for GBM in pancreatic, could NovoCure get back double-digit growth in fiscal '27? Generally talk about big picture, how we should be thinking about the revenue profile for this company going forward?

Thank you, Vijay. I'll comment first on big picture themes around the GBM business and the Pax launch, and I'll turn it to Christophe to talk a little bit more about how we think about the long-term financial forecast. So first, we are very pleased to see growth last year in our GBM business, not just international growth and opening new markets, but also in the core original business in the U.S. growing. And as we've said before, we believe there are many more patients that can benefit from the therapy. As we currently have a penetration rate in our active markets of around 40%.

And so what we've continued to do is invest into our GBM business, both the capabilities on the sales and marketing side to essentially dual-cover doctors. So if we have a call in a community practice for pancreatic cancer, that same rep is now able to reach the community doctors to detail on GBM. We've also improved our sales operations and targeting capabilities. And we really do feel like we've -- in our core businesses and particularly in the U.S., we have the right team and the right skill sets in place right now to continue driving growth.

And so we think that foundation alone is really an exciting way to think about the next few years. And what we've seen in panc right now gives us really an incredible amount of confidence that we can turn this into the second major revenue pillar for the company in the coming years.

Yes. And maybe just to add to this. So to reiterate our strategies very clearly to get to double-digit revenue growth and also to profitable growth and to profitability. Now we gave you a revenue guide for this year that is ranging from 5% to 8% at the midpoint, 7% growth, with what I would classify as very initial contributions from new indication launches. So with more material contributions from new indication launches, we expect to get into the double-digit revenue growth in the future.

And our next question will be coming from the line of Lawrence Biegelsen of Wells Fargo.

I wanted to ask, of course, about pancreatic launch. When we look at newly diagnosed GBM, I mean, we only have one quarter here, but it looks remarkably similar on prescriptions better on active patients. I know it's early, but what can you say when comparing prescription launch in the U.S. and active patient ramp for newly diagnosed GBM to pancreatic? Let me just -- I'll just ask all my questions upfront. Was there any pent-up demand for Q1 for Pan and then just OUS timing, remind us of that, please.

Larry, this is Frank. Thank you for the question. I would say we are -- we haven't really focused on comparing panc to our prior GBM launch for a technical aspect, which is simply that, in GBM, we have been approved in second-line therapy and had existing relationships and then in first-line therapy. The data had been out for over a year before the FDA approval. So it's sort of, on a technical basis, it becomes difficult to take an exact comparison point.

So what I would anchor back to is the almost 900 prescribers who sought certification in the first month of commercial availability, that was -- as we said before, that was multiples of the certification levels that we saw in our LUNAR launch. We did -- we do think that reflects some pent-up demand, but I don't -- I wouldn't -- I would absolutely not describe it as a bolus of patients waiting and that it then normalize to a different level. We do just see really strong interest from the community in using Optune Pax to treat their locally advanced pancreatic cancer patients.

And OUS?

OUS, yes. I'm sorry. Thank you. In terms of OUS, Christoph, can you remind me of the timing?

Yes. So we said second half for both German -- TUV approval as well as for Japan approval.

Yes. And all the applications are in we're now just sort of waiting for those submissions. And if everything proceeds as expected, we would launch in the second half in those regions.

I mean just maybe 1 follow-up up, Frank. I mean do you think pancreatic could ultimately be bigger than GBM overall? I think you've said that in the past.

Well, I certainly -- so I think the pancreatic -- I think in our current indication in locally advanced pancreatic cancer, we believe there's around 16,000 patients, which is already bigger than the eligible patient population for Optune Gio. As we build our evidence base out and when we're able to secure those additional FDA approvals, it just keeps growing from there. So we are absolutely committed to success in this indication and we think it has trended -- as I said before, to have a tremendous potential to be our second major revenue driver. And ultimately, the population is bigger than the population for our current business.

And our next question will be coming from the line of Emily Bodnar of H.C. Wainright.

Congrats on the strong first quarter. Curious if you could comment a bit on your confidence for converting the full 169 prescriptions to access patients and if you can kind of comment on what the average timing has been to converting patients from prescription to active therapy?

Yes, appreciate the question because it was a big difference between prescriptions and active patients, and that simply reflected the timing of having 1 month at the very end of the quarter. So we don't intend to give the number of starts every quarter, but what I will highlight is that we had 90 starts, which led to that active patient number. And we saw typically about 2 weeks -- a little bit less than 2 weeks from a prescription to a start. And so those -- that $163 million reflects a lot of prescriptions right at the very, very end of the quarter that we'll be talking about on the next earnings call.

And maybe on metastatic cancer. Obviously, you have the Pinova 4 data and then you also touched on kind of potential synergy with RAS inhibitors. Maybe just kind of talk about general strategy moving forward for the metastatic setting.

So thank you for the question. Yes, we were very pleased to read out the results of the PANOVA 4 study. As a reminder, our single-arm study in metastatic pancreatic cancer patients using a combination of gemcitabine atezolizumab Ross PD-L1 inhibitor and TT fields. The primary endpoint was met. The primary endpoint was disease control rate, and it was significantly increased as a result of using the therapeutic regimen in Pan from the historical 48% into 74 I think that the most important message and takeaways from the PANOVA 4 study is seeing again, the relevance of PTCL therapy as a therapeutic approach to be developed in the metastatic setting in pancreatic adenocarcinoma, and following our demonstration of the clinical effectiveness in locally advanced pancreatic cancer in the PANOVA 3 study and the approval that paves the way to continue the studies and development in this space.

And the population use TTFields therapy at a very desirable usage rates. They use it for the entire protocol indicated duration of treatment. RECONNECT So again, a great evidence of PDF's role in metaancreatic cancer, and we continue to explore directions may come back to this regimen at a later point in time.

And our next question will be coming from the line of Jessica Fye of JPMorgan.

This is Tammy on for Jess. I wanted to ask for option tax, you mentioned the backlog of staff from the funnel. So I was wondering if the conversion from prescriptions to patients on therapies going on as expect -- and what do you expect the ultimate to be from those getting prescriptions to those patients who tensilinitiate on therapy?

Thank you for the question. We -- again, we wanted to be clear that with 1 month essentially 1 month and a few days of activity where we could take prescriptions and convert to starts. It's hard to give definitive answers around trends about the rate at which prescriptions will convert to starts. But the consistent theme I want to emphasize is that we are very pleased with the results so far. We -- in particular, I'm really proud of our team who helps the patients, our technical support team that's helping our patients. This is a new patient population for them.

And I think the main takeaway in that first month is that we could execute quickly to move from prescription to start -- and as I mentioned, we had a good strong correlation between active patients at the end and the starts that occurred in the quarter, which means we're giving them the right support to make the treatment feasible and practical.

And I'm showing no further questions at this time. I would like to turn the conference back to Bill Doyle for closing remarks.

I'd like to end the call today by noting that NovoCure was able to maintain the momentum of the fourth quarter last year with strong and consistent execution in Q1. We're very pleased to see growth in both double-digit growth in both active patients and net revenue compared to Q1 last year and very promising early signals, both from our LUNAR launch in Japan and, of course, from our Optimum pack launch in the U.S. Our 2026 catalysts remain on track. We look forward to continued reporting on the developments in the commercial business as well as the top line data from Trident up next in next quarter.

We didn't talk about it much in this call, but our company remains focused not only on achieving the double-digit growth that Christoph underlined, but also on bringing the company to profitability. And we were also very pleased with our numbers in that regard. And we are focused as we have updated in our guidance on our path to profitability. So thanks to the team at Novocure, thanks to our patients and clinicians. And it's an exciting time to be at the company, and we look forward to reporting our progress in the next quarters.

And this concludes today's program. Thank you for participating. You may now disconnect.

Good day, and thank you for standing by. Welcome to the NovoCure Fourth Quarter 2025 Earnings Call. [Operator Instructions] Please be advised that today's conference is being recorded.

I'd now like to hand the conference over to Adam Daney, Head of Investor Relations. Please go ahead.

Good morning, and thank you for joining us to review NovoCure's Fourth Quarter and Full Year 2025 performance. I'm joined on the phone today with our Executive Chairman, Bill Doyle; CEO, Frank Leonard; and CFO, Christoph Brackmann. Other members of our executive leadership team will be available for Q&A. For your reference, slides accompanying this earnings release can be found on our website, www.novocure.com, on the Investor Relations page under Quarterly Reports.

Before we start, I would like to remind you that our discussions today during this conference call will include forward-looking statements, and actual results could differ materially from those projected in these statements. These statements involve a number of risks and uncertainties, some of which are beyond our control and are described from time to time in our SEC filings. We do not intend to update publicly any forward-looking statements, except as required by law. Where appropriate, we will refer to non-GAAP financial measures to evaluate our business, specifically adjusted EBITDA, a measure of earnings before interest, taxes, depreciation, amortization, and share-based compensation. We believe adjusted EBITDA is an important metric as it removes the impact of earnings attributable to our capital structure, tax rate, and material noncash items and best reflects the financial value generated by our business.

We do not provide forward-looking guidance for adjusted EBITDA on a GAAP basis due to the inability to predict share-based compensation expenses contained in the reconciled GAAP measure of net income without reasonable efforts. Reconciliations of non-GAAP to GAAP financial measures are included in our press release, earnings slides, and in our Form 10-K filed with the SEC today. These materials can also be accessed from the Investor Relations page of our website. Following our prepared remarks this morning, we will open the line for your questions.

I will now turn the call over to our Executive Chairman, Bill Doyle.

Thank you, Adam. I'll begin this morning with a brief review of our 2025 accomplishments and look ahead to 2026. Our CEO, Frank Leonard, will then discuss recent commercial updates. And finally, our CFO, Christoph Brackmann, will walk through our fourth quarter financial performance and 2026 guidance before opening the line for questions.

2025 was a year of progress and change at NovoCure. We generated a record $655 million in net revenues last year, an 8% increase from 2024. We presented final data from 2 large randomized trials in plenary sessions at major medical congresses, followed by publications in leading medical journals. We submitted PMA applications to the FDA for the use of TTFields therapy to treat pancreatic cancer and brain metastases from non-small cell lung cancer. And we rolled out product enhancements designed to improve the TTFields therapy experience for both patients and physicians.

2025 was a strong year of execution, setting the stage for a catalyst-rich 2026. We expect to reach a number of regulatory, clinical, and commercial milestones this year. The first milestone was reached earlier this month with the approval of Optune Pax for the treatment of locally advanced pancreatic cancer, and we have submitted regulatory filings for Optune Pax in Europe and Japan. We expect Optune Pax to be a significant contributor to our long-term growth and are eager to begin treating patients in the coming weeks. We also expect a decision from the FDA on our brain metastases PMA later this year.

On the clinical front, we are on track for top-line readouts from both the PANOVA-4 and TRIDENT trials this year. PANOVA-4 is a Phase II trial exploring the use of TTFields, atezolizumab, a checkpoint inhibitor, and chemotherapy in metastatic pancreatic cancer with top-line data anticipated next month. TRIDENT is a Phase III trial exploring earlier use of TTFields concomitant with radiation and temozolomide in newly diagnosed GBM, which we expect to read out in Q2. We are also on track to complete enrollment of our next Phase III trial, KEYNOTE D58, studying Tumor Treating Fields, temozolomide, and the checkpoint inhibitor pembrolizumab in newly diagnosed GBM by year-end.

Turning to our commercial portfolio. We anticipate a number of national or regional launches of our 3 products this year. This includes Optune Gio launches in Spain, Czechia, and the Canadian province of British Columbia, and Optune Lua launch in Japan and Optune Pax launches in the U.S. and Germany.

Before I hand the call over to Frank, I would like to touch on one update from this morning's press release. Dr. Nicolas Leupin, our Chief Medical Officer, resigned from the company effective February 25. Following Nicolas' departure, we have decided to combine our scientific and clinical organizations to accelerate our R&D execution and shorten the cycle from scientific insight to clinical relevance. Dr. Uri Weinberg, our Chief Innovation Officer, will now also assume the role of Chief Medical Officer. Dr. Weinberg joined NovoCure in 2008 and has been instrumental in establishing and leading a number of our scientific and research and development functions over the years. Uri is well qualified to take over this dual mandate. I would like to personally thank Nicolas for his contributions to NovoCure and to congratulate Uri on his expanded role.

With that, let me hand the call to Frank to walk through recent updates.

Thank you, Bill, and good morning. I'm excited to speak to you in my new role as CEO and at a time when NovoCure is evolving into a multi-indication platform company. 2025 was our most successful commercial year to date, and we expect to carry this positive momentum into 2026. Our business remains core, our GBM business remains core to our commercial operations. In 2025, we saw substantial active patient growth across all our major markets. OUS markets were the biggest driver, including 10% year-over-year growth in Germany, 19% in France, and 29% in Japan. We also saw 4% active patient growth in the U.S., which had been flat in recent years.

In 2026, we expect growth rates to stabilize in the low to mid-single-digit range as these markets continue to mature. We should also see a tailwind from new market launches in Spain, Czechia, and British Columbia, though first-year revenue contributions are likely to be modest.

Turning to Optune Lua. We are preparing to launch in Japan. Japan represents a promising opportunity for Optune Lua, given first and second-line use of immune checkpoint inhibitors is standard of care in Japan. We expect to receive our final reimbursement approval in the coming weeks. We will then be able to launch in Japan with national coverage and pricing. As we've previously stated, the Optune Lua launch has been slower than we originally projected in the U.S. and Germany. We have rightsized our marketing spend based on the current demand and are prioritizing investments in indications with a higher return potential, such as pancreatic cancer.

Finally, I will turn now to our newest FDA approval, Optune Pax for locally advanced pancreatic cancer. We are very pleased to have received FDA approval and appreciate the agency's partnership throughout the review process. The industry standard time for PMA reviews is between 9 to 12 months. In the case of Optune Pax, the FDA review was completed exactly at the 180-day mark, with approval received on February 11. We've commenced our Optune Pax launch and are now certifying prescribers and receiving prescriptions. We have designed the launch plans for Optune Pax to make prescribing and starting patients as easy as possible for physicians, including emphasizing the use of our HCP portal to enable digital prescriptions.

We are also giving the prescriber more discretion in patient selection rather than detailing to a preferred patient profile. We are also able to leverage our established torso sales force for the Optune Pax launch. The existence of a trained team significantly lessens the educational burden of onboarding a new team and enables us to take advantage of the established team's deep knowledge of TTFields therapy. This team has built extensive connections with physicians, which will prove invaluable given that some medical oncologists treat both lung and pancreatic cancer patients.

There are a lot of similarities between GBM and pancreatic cancer that give us confidence in both the market opportunity and our ability to commercialize Optune Pax. Both cancers are typically diagnosed at a late stage and are incredibly difficult to treat. Both cancers have properties that limit the bioavailability of systemic therapies, making these tumors prime targets for a physical treatment approach. And both tumors have limited approved therapeutic options for patients. We are eager to begin treating patients in the coming weeks.

Now is an exciting time to step into the CEO role at NovoCure. Since I joined the company in 2010, we have had numerous clinical, regulatory, and commercial milestones across multiple indications, and we are now primed to enter our next era of substantial growth. I'm thankful for the opportunity to lead at such an exciting time, and I want to thank all of my colleagues for their dedication and support during the transition.

I'll now pass the call over to Christoph to review our Q4 and full-year 2025 financials as well as our guidance for 2026.

Thank you, Frank. We closed 2025 with continued momentum, delivering record net revenue for both the quarter and full year. Fourth quarter net revenue was $174 million, and full year net revenue totaled $655 million, representing 8% year-over-year growth for both periods. Growth was primarily driven by continued expansion in ex-U.S. markets, particularly Germany, France, and Japan, reflecting solid underlying demand and increased active patient count. Foreign exchange provided a tailwind of approximately $5 million in Q4 and $11 million for the full year compared to 2024.

We recognized $3.5 million from Optune Lua claims in the quarter, including $2.4 million from non-small cell lung cancer. For the full year, Optune Lua revenue was $10.4 million, including $5.8 million from non-small cell lung cancer patients. I would also like to briefly address the recent Medicare billing situation. Earlier this month, CMS notified us that our billing privileges were halted due to an administrative issue identified during the DME supplier revalidation process. We engaged with the agency quickly, submitted a corrective action plan the following business day, and completed our required reinspection. Two days ago, we were notified that CMS rescinded the revocation and directed that our Medicare enrollment and billing privileges be reinstated retroactively to December 17, 2025. As a result, we do not expect any negative impact on revenue recognition from this matter. We are pleased that the issue is resolved and are appreciative of the agency's partnership in addressing the issue swiftly.

Looking ahead to 2026. This morning, we issued annual net revenue guidance at constant exchange rates of $675 million to $705 million, representing year-over-year growth between 3% and 8%. This assumes Optune Gio net revenue growth in the low to mid-single digits and net revenue contributions from non-GBM products of $15 million to $25 million compared to $10 million in 2025.

Moving down the P&L. Fourth quarter gross margin was 76% and 75% for the full year compared to 79% and 77% for the fourth quarter and full year 2024. The decrease was primarily driven by a decrease in prior period collections in the U.S. and increased costs associated with the HIV rates and tariffs. For 2026, we expect gross margin in the mid-70s percentage range. Research and development costs in the quarter were $61 million, an increase of 19% from the same period last year, and $225 million for the full year, an increase of 7%. The quarterly increase was driven by increased costs related to the KEYNOTE-58 and LUNAR-2 Phase III trials and regulatory costs.

Sales and marketing expenses in the quarter were $69 million, an increase of 2% from Q4 2024, and full year sales and marketing expenses were $240 million, flat year-over-year. The increase in the quarter was driven by increased marketing activities related to new indications. G&A expenses for the fourth quarter were $43 million, a decrease of 41%, and $178 million for the full year, a decrease of 6% from 2024. The primary driver for the quarter was lower share-based compensation expenses related to 2020 PSUs triggered by the approval of Optune Lua in 2024. As noted in the 10-K today, we will have a similar charge in Q1 triggered by the Optune Pax approval.

Net loss for the quarter was $24 million with a loss per share of $0.22. Full-year net loss was $136 million or $1.22 per share. Adjusted EBITDA in the quarter was negative $16 million and negative $34 million for the full year. Our cash and investment balance at the end of Q4 was $448 million. In the fourth quarter, we repaid $561 million of convertible notes in cash. We believe our current funds available, coupled with diligent expense management, will provide the necessary bridge as we bring new revenue streams online. Therefore, we have decided not to go beyond the $200 million already drawn from our current credit facility.

As we look ahead to 2026, we are determined to make material progress towards our goal of driving profitable growth in the coming years. This morning, we issued adjusted EBITDA guidance of negative $20 million to breakeven for full year 2026. Overall, this reflects an acceleration of our plans to achieve adjusted EBITDA breakeven, driven by both our expectations of revenue growth as well as diligent expense management across the organization.

With that, I'll turn the call back to the operator for Q&A.

[Operator Instructions] Our first question comes from Jason Bednar with Piper Sandler.

Congratulations on the recent approval of Optune Pax. There's probably too many topics to choose from this morning. There's a lot going on here. But why don't I start first with the guidance? This is obviously a first for NovoCure, glad to see it. So can you talk about why it made sense now to give the guidance versus past years? And then can you break out some of the contributions included within the revenue guide around maybe things like you're assuming with new international markets? I think you called out Spain, Czechia, and Canada. And then as well as whether you're assuming anything in the revenue and EBITDA guide from previously denied claims.

Thanks, Jason. This is Frank. I'll start with top line, and then I'll hand it to Christoph to go into some of the assumptions. First, I just want to also say thanks for the recognition of the many positive headlines we had in the last quarter and closing out 2025. It certainly has been an exciting time here at NovoCure. Jason, as I came into the role as CEO, one of the things we did is really try to spend as much time with our investor community as possible. One of the core messages that we've heard is that we need to speak more clearly in terms of setting expectations of what we can accomplish in the coming year. And we're taking that first step today with guidance where we really want to send the signal first at the top line that we are committed to returning the company to steady growth.

And this is the first year where the Optune Pax will build a foundation that we can make even stronger going out to 2027. Two is that we're sending a very clear signal that we want to drive to adjusted EBITDA breakeven as a possibility this year because we've heard the message loudly and clearly that we need to have both growth and profitability. And lastly, I think I just would emphasize that as a company, we're trying to send a signal that we're moving up the maturity curve. We've been a public company for 10 years. We think this is a necessary and important step to take right now. So Christoph?

Yes. Thank you. So yes, on the specifics on guidance or the underlying assumptions, on the revenue side, there's really 3 areas that we are thinking of in terms of growth. There's our GBM business in established markets where we expect growth in the low to mid-single-digit growth -- mid-single-digit range. Then we have GBM in newer markets. So an example of this would be Spain or Czech or also the recent approval in Canada that we announced. Now these will be modest contributions in 2026 as we ramp in 2026 in those markets. And then the third bucket of growth would be new indications. And yes, that's also where -- as you can see, we say we are expecting contributions in the range of $15 million to $25 million. So growth over prior year connected to the launches that we have with Optune Lua in Japan and Optune Pax in the U.S., as well in other markets.

Our next question comes from Vijay Kumar with Evercore ISI.

This is Kevin on for Vijay. Just one on Optune Gio. It looks like the guidance assumes a low to mid-single-digit revenue growth. My understanding is that this market, over the long term, is more of a mid-single-digit growth type of market. Is this just conservatism embedded in the guidance? Or are you seeing a change in the market growth rate?

Thank you for the question, Kevin. No, we are not seeing -- we're not signaling a conservatism or a moderation. We're trying to signal that we believe the -- number one, we believe there are still many patients who will benefit from Optune Gio with glioblastoma. As a reminder, we think in our mature markets, we're on average, about 40% of the patients are getting a prescription for Optune Gio. And we think based on the data that we've already generated, that number should be significantly higher. And so the range is really intended to reiterate our ability that we've shown last year to grow in that mid-single digits range, but at the same time, to provide that guidance of a band that reflects all of the assumptions that could come into revenue, including -- just including the various puts and takes on when revenue comes online.

Our next question comes from Larry Biegelsen with Wells Fargo.

Congrats on the Pax approval as well coming in earlier than expected. So on that product, can you just talk about, based on the approved label, how do you think the device will be prescribed? And specifically, what are the lessons learned from the lung launch that you can apply here to ensure success? And I have a follow-up regarding the guidance.

Yes. Thanks, Larry. This is Frank. I'll start, and I might turn it to Christoph at the end to just comment on the market size itself. So first, we're very pleased with the approval for Optune Pax, both the label that we received as well as the timing. And I think that the quality of the data that we brought to the FDA should really be underlined in that sense that we were able to secure this 180-day review cycle. Optune Pax is being approved for locally advanced pancreatic cancer in a first-line setting in concurrent use with nab-paclitaxel plus gemcitabine. And so I want to emphasize that's a first-line patient with locally advanced disease, so still focal disease. We think this is a highly motivated patient population. It's a population also that has had really very limited treatment options to date. And we think this fits very nicely with our overall value proposition to physicians and to patients, that we can bring this unique physical approach to layer on top of the existing systemic therapies that, quite frankly, have not been successful enough in pancreatic cancer.

So to answer the question directly, we believe within that label, that really is the core population that we can pursue first, and we're very happy that that is because we believe it's a highly motivated patient and a highly motivated physician.

And Christophe, could you comment a bit on the market assumptions?

Yes, sure. So we estimate the TAM for locally advanced pancreatic cancer in the U.S. to be 15,000 patients on an annual basis. This is down from about 60,000 patients being diagnosed with PDAC on an annual basis, and then about 1/3 is in the locally advanced pancreatic setting.

Our next question comes from Jonathan Chang with Leerink Partners.

This is Albert Aginis on for Jonathan Chang. Congrats on the approval of Optune Pax. Regarding that topic, how much sales force are you allocating for Optune Pax? Do you foresee or have you recruited new commercial team members to accommodate for this launch? Or is it more of a reallocation of the current commercial team?

Thanks, Albert, for the question. We are very pleased that we have an established team that we've trained over the last 2 years to detail our Optune Lua product. That team that's already in the field and fully established is being -- repurpose is probably the wrong word, but I should say, tasked now with leading our pancreatic launch. So we're not adding incremental sales headcount at this time. We are simply leveraging the team that we have.

Our next question comes from Emily Bodnar with H.C. Wainwright.

Congrats on the Optune Pax approval. So you guided to the $15 million to $25 million in revenue for Optune Lua and Optune Pax this year. I'm curious if you could kind of give some more detail into how we should be thinking about revenue contribution, specifically for Optune Pax this year, as you're kind of getting reimbursement plans in place? And then maybe a follow-up to the prior question. How much of your sales and marketing force that you already have is kind of in place for HCPs that are going to be covering locally advanced pancreatic patients based on your GBM and non-small cell lung cancer launches?

Excellent. Thanks, Emily. I'll start, and I'll turn it over to Christoph. Just as a reminder for everyone, as we launch in a new indication, we do, as a medical device, need to go through a process of working with the payers to establish coverage policies and in some cases, having updates to our contracts with the payers in the United States to then move towards a position where we have a more direct correlation between active patients and revenue. At the start, we will start all of the patients, and we'll begin working through an appeals process, just as we've done with glioblastoma and lung before, and it's a process that we're quite familiar with, and we're confident we're going to be able to work through it.

But that will mean that in this launch period, you will see revenue not correlate directly with active patients because there will be a lag as we establish the coverage policies and the payment policies with payers in the United States. I'll flag that as always, for us, one of the most critical steps in that process is to secure an inclusion in the NCCN guidelines for the treatment of locally advanced pancreatic cancer. We have submitted that application, and we're hopeful to be included soon. And we think that will be one of the material steps this year towards securing the coverage policies that will drive some revenue this year, but ultimately, it will be revenue that will come next year. Christoph?

Yes. I think the only thing to add to what you said, Frank, maybe would be that similar to what we said for Optune Lua, we expect it will take us about 1 to 2 years to get coverage on a more routine basis for commercial payers. And that's also connected to the launch success, right? The more patients that we have on therapy, the easier we'll get to get coverage policies.

And Christoph, there was also a question about sales and marketing expenses.

Yes. So in terms of sales and marketing expense, as we -- I mean, as Frank alluded to earlier, we are basically reusing this field force. So when we built the field force for NACLC last year and earlier, basically, we thought of it as a Torso-focused field force. And so from a field force perspective, there is no incremental -- very small incremental spend, if any, incremental spend on the pancreatic launch will be on the marketing side. Part of that already we had in Q4 of last year.

That concludes today's question-and-answer session. I'd like to turn the call back to Bill Doyle for closing remarks.

So in closing, I'd like to underline that 2025 was a year of strong execution at NovoCure with record net revenue and record active patients. We're very pleased with our 2 Phase III presentations and publications and the 2 PMAs submitted, which we think really create the foundation for success in the future. We're set to maintain that momentum with a catalyst-rich 2026. We're pleased to have already received the PMA approval for PANOVA for Optune Pax, and to have submitted the regulatory filings in the EU and Japan. And we're looking forward to the top-line results from PANOVA-4 and TRIDENT.

On the commercial side, we expect to maintain our momentum as has been discussed on this call, and we're really excited to bring our products to patients in new markets, particularly Spain, Czechia, and in British Columbia. We've really tried to emphasize to everyone today that we're focused on driving to profitability. As Frank said, 10 years in the public markets, we're ready to guide, and we're ready to make that one of our primary goals. We see a path to profitability and, in fact, the potential to reach adjusted EBITDA breakeven this year. With that, I'd like to end by thanking you all for your continued interest and focus on NovoCure. And in particular, I need to thank my colleagues. 2025 was a year of accomplishment and change as we position the company for the exciting future that we see ahead of us.

This concludes today's conference call. Thank you for participating. You may now disconnect.

Great. Good morning, everyone. My name is Jess Fye. I'm a biotech analyst at JPMorgan, and we're continuing our 44th Annual Healthcare Conference today with NovoCure. First, you're going to hear a presentation from the company, and then we're going to have a Q&A session. [Operator Instructions]. But with that out of the way, let me turn it over to the company's CEO, Frank Leonard.

Thank you, Jess. It's my privilege to be here today to present NovoCure's preliminary 2025 results as well as look ahead to a catalyst-rich year in 2026. For those of you who don't know me, I have taken over as CEO just a few months ago. However, I've been with the company now for 15-plus years. And prior to that as a venture capital investor and part of the team that helped to bring the first institutional investments into NovoCure.

And I -- through that time, I've covered multiple areas for the company, including our product development, corporate strategy, reimbursement groups and then more recently, leading us through a reorganization of our commercial organization to drive us back to growth. And I'm excited because as much as we are proud of our past accomplishments, 2026 is a year of multiple catalysts and we'll detail those as I move forward.

But first, let's set the stage on NovoCure, the company itself. What are we today? First, NovoCure has developed, pioneered and commercialized an effective wearable cancer therapy that is currently a standard of care for glioblastoma patients. We built ourselves from there to have successful clinical trials across multiple indications that we'll discuss today. This is a unique way of treating cancer. And in a moment, I'll go back to our core mechanism of action and how it is unique from other therapies pioneer to date.

We're proud that we've built a market-leading position, not only in the United States but across key markets around the world to help patients with glioblastoma, which as a reminder, is the most deadly form of brain cancer.

We are also excited as a company that as we look ahead to 2026 and beyond, we have the ability to continue expanding both within glioblastoma, growing our existing markets as well as entering new markets, and from there, launching in additional indications in pancreatic cancer and brain metastases from non-small cell lung cancer.

We'd also like to be sure that we're communicating these growth opportunities in light of a clear commitment to a path to profitability starting first with our commitment to reaching adjusted EBITDA breakeven.

So let's go to Tumor Treating Fields, our core therapy and what it is. Tumor Treating Fields are alternating electric fields that target the electrical properties of cancer cells. For those of you coming to the story from a biotech or a biology background, I'd encourage you to think about cancer cells in the accumulation of calcium ion. Cancer cells are unique through many different ways, their electrical properties transform, the introduction of a substantial influx of calcium ion inherently changes the capacitance of a cancer cell, making it unique relative to healthy cells.

For those of you coming to the story from a med tech background, I'd ask you to think about the therapy in terms of how electric fields are typically applied in medicine. We've historically built devices at low frequencies and direct current that are stimulatory and have the ability to do things like TENS units and pain relief or bone growth stimulators.

On the other side, with high-frequency devices, we can induce heating and ultimately ablation. We are applying intermediate electric fields that until our founders' research were thought to be inert. Our unique insight is knowing that those fields have a selective and unique effect on cancer cells due to the differentiated electric properties of those cells.

So what have we done with this therapy over the 25 years of our company's existence? We have demonstrated success now across a wide range of solid tumors, where patients are desperately in need of additional options. Our business started first with success in glioblastoma where we were able to show a 5-month improvement in median overall survival for patients with glioblastoma. Most importantly, as you look at the Kaplan-Meier curve, our device, for the first time, moved to the 5-year survival for glioblastoma patients above 13% for the intent-to-treat population.

But I'll highlight that we have additional evidence showing that for patients who use our device at the maximum available usage per day and consistently, they were actually able to outpace that result and show strong durable long-term survival.

From there, we moved on to our successful LUNAR study in non-small cell lung cancer. Our LUNAR trial was in the second-line setting for Stage IV metastatic non-small cell lung cancer. Patients were able to use Tumor Treating Fields with a backbone systemic therapy or a systemic therapy alone and the systemic therapy included a physician's choice of either docetaxel or an immune checkpoint inhibitor.

In the intent-to-treat population in this trial, we demonstrated a significantly significant improvement in overall survival. And specific to the patients who were treated with immune checkpoint inhibitors plus Tumor Treating Fields, we show that the concurrent use of those 2 therapies produced a profound effect on clinical outcomes, specifically survival. And as I'll talk about in a moment, we believe this outcome from this trial shows that when you exert physical stress on a cancer cell, you achieve not only our primary direct cytotoxic effect, which is an antimitotic effect by inhibiting the mitotic spindle formation but also a cascade of downstream stress signaling from the physical effect of Tumor Treating Fields on multiple proteins within the cell and through that stress signaling and upregulation of the immune response to tumors.

More recently, in 2025, we announced annual results from 2 additional significant pivotal studies. First, we announced and published our data from the PANOVA-3 study in locally advanced pancreatic cancer as a first-line setting. We demonstrated again a statistically significant improvement in median overall survival with a 2-month OS benefit in pancreatic cancer.

We're also very excited that this trial showed a 6-month extension in progression -- sorry, in pain-free survival for patients with pancreatic cancer. And we note that pain-free survival is one of the most meaningful clinical endpoints for patients treating this disease.

I'd also highlight that if you look between glioblastoma and pancreatic cancer. These 2 tumors have something unique in common. Both have a low bioavailability for drugs. They are difficult tumors to treat with systemic therapies. In glioblastoma, over the last 25 years, despite hundreds of trials, there has been 1 systemic therapy approved. In pancreatic cancer to date with an even greater number of clinical trials over the last 25 years, there have been 5 drugs approved. These are 2 tumors that I'll highlight through the presentation that are in specific need of a biophysical approach to augment the incredible systemic therapies that are being developed today.

And lastly, I'll note that in the September time frame, we also announced and published the final results from our METIS study for patients with non-small cell lung cancer that had metastasized to the brain. In this study, patients were given SRS, stereotactic radiosurgery, to treat their brain tumors and either left for watchful waiting or added or given Tumor Treating Fields as an additive therapy. In this trial, we showed a doubling of the time to intracranial progression when Tumor Treating Fields was layered on top of the SRS treatment.

Now looking back to 2025 to summarize our results. First, I want to highlight that we are exiting 2025 in a strong financial position due to the growth that we were able to drive in our core GBM business. We saw growth in all of our active markets in glioblastoma, and I'll drill down on that in just a moment. That growth led to us posting $655 million of revenue in our preliminary results that we announced this week, which represents an 8% revenue growth year-over-year.

As I highlighted on the previous slide, our success in pancreatic cancer and in brain mets is enabling us to move forward with new clinical indications, and we have completed filings for both our PANOVA-3 data with FDA and our METIS data with FDA.

Lastly, as a medical device that's worn by patients 24 hours a day often, we have a unique relationship, not just with the physician who is prescribing to treat the patient, but also with the patient who is using our device to extend their survival. As such, we aim to strengthen our relationship with that patient through the introduction of better technology to improve their ability to physically use our device as well as through digital technologies that enable them to interact with us more in real time, to understand their treatment, to ask for troubleshooting and to gain clarity over what needs to come next in their treatment with the device specifically. That, we believe, will enable the physician -- the patients to use the device more consistently through the day. And based on our past results, we believe that increased usage can drive a longer duration of therapy.

So let's drill down and look at our GBM business last year in 2025. Across the globe, we drove a 9% increase in active patient volume. That growth comes from all of our key markets, and I'll highlight that in Japan, we grew our active patients by 29%, by 19% in France and 10% in Germany as well as showing growth in all of our smaller markets around the world.

I'm also particularly excited to note that our U.S. GBM business has grown by 4% year-over-year based on a strong Q4 close. We are currently active in 8 markets around the world, and we believe, this is -- that our results in 2025 represent the strong work of our teams over the last 3 years to reevaluate, reprioritize and then execute upon opportunities that were there for us to take and by extension for patients to gain access to this important therapy.

So looking ahead commercially, we do intend to continue growing in both of our approved indications. In glioblastoma, around the world today, after our 2025 results, we believe in our key markets, our penetration rate is somewhere in the range of 35% to 40% of eligible patients depending on the country. We know that based on our strong pivotal trial results, we can drive that adoption higher. This is a disease where without our device, the 5-year survival rate drops below 5% and with it, it moves above 10%. We want to continue emphasizing the benefit of the therapy as well as introducing new data sets to further confirm the benefit of Tumor Treating Fields, and we'll elaborate on those in a moment.

We also plan to capitalize on selective opportunities to increase our geographic footprint, and I'll note that in 2025, we announced we have achieved national reimbursement in Spain for Tumor Treating Fields for the treatment of glioblastoma. Additionally, we're going to selectively look for new countries where the opportunities may be smaller, but they are substantial and take those opportunities where we think they make sense financially.

Now turning to our existing business in non-small cell lung cancer, which is treating patients in the second line of Stage IV non-small cell lung cancer. We have launched in the U.S. and Germany, and we have acknowledged that our launch is behind plan and has been challenged. We currently have 122 patients on therapy in these 2 markets. What we are stating today is that we recognize this challenge, and we have accordingly addressed the sales and marketing spend within our existing lung business in the existing markets appropriately to recognize the challenges that we're facing.

Looking ahead, though, we do see markets where the treatment paradigm today for the second-line patient in Stage IV non-small cell lung cancer does justify continued investment. And we have consistently highlighted that in Japan, patients are more often continued on an immune checkpoint inhibitor from the first line to the second line. And we note that our discussions with KOLs in Japan have been favorable in terms of the benefit of adding Tumor Treating Fields into the second-line setting for patients in Japan.

So while we have seen challenges in this market, and we are making the necessary financial decisions to recognize those challenges, we will continue to invest selectively where we see the potential to build a sustainable business.

Looking ahead, as I've already highlighted, we have 2 exciting launches on the horizon. Again, our launch in pancreatic cancer will be in locally advanced patients in a first-line setting. We believe the total addressable market includes around 15,000 patients in the United States, and we are anticipating a launch in Q2 following a regulatory approval in the same quarter.

To put this in perspective, this market is slightly larger at 15,000 patients than the addressable market that we have in our GBM patient today -- GBM patients today. And as I've noted, we believe that in pancreatic cancer, where there have been so many failures after so many attempts and billions of dollars spent to address this tumor with a systemic therapy the physicians understand the unique benefit that biophysical approaches will bring to patients in need.

Moving towards the end of the year, we anticipate a Q4 regulatory approval and launch for our indication, treating patients with brain metastases from non-small cell lung cancer on the basis of our METIS study.

This market, again, at 16,000 potential on-label patients in the United States is slightly larger than our existing market for glioblastoma. And so taken together, we believe these 2 markets put us on a path for a multiyear growth trajectory that will enable us to build a bigger and sustainably profitable business, treating patients in these 3 indications.

Now I've spoken before, but I want to tie together some of the themes that we hope to address in the coming years as we think about both our commercial business and our R&D portfolio. Tumor Treating Fields in the petri dish in animal models has shown a broad ability to kill cancer cells across multiple cancer cell lines and in tumor models in multiple different animal models. We really haven't seen a reason for Tumor Treating Fields not to work scientifically when you apply it against the cancer cell.

What we have seen is that this is a device that must be worn 24 hours a day and used by a physician who more often than not is comfortable using drugs over devices. And we need to, as a company, lean into and understand that our device has a specific set of unique benefits that on the flip side, while maybe, I would say, advantages that allow us, in some respects, to target tumors that we cannot otherwise access. We do also, at the same time, have to recognize that wearing a device will also be something that we have to introduce into the paradigm. And accordingly, we want to invest very judiciously where we think the device can be recognized by both the physician and the patient as the most unique opportunity to address the clinical need.

So specifically, as I've mentioned before, 2 areas that we want to highlight today are tumors with low bioavailability for systemic therapies and tumors where our ability to regulate -- to upregulate the immune response through enhanced stress signaling of the cell will produce a better effect for immune checkpoint inhibitors against that target.

With that, I'd like to turn to review our existing R&D portfolio in light of these 2 unique aspects of Tumor Treating Fields. First, we are excited that we will -- we have completed and will announce top line results for our PANOVA-4 study in Q1 of 2026. PANOVA-4 is in the metastatic pancreatic setting, first-line setting for metastatic pancreatic cancer, where the patients will receive Tumor Treating Fields plus atezolizumab plus gemcitabine, nab-paclitaxel doublet, which is building on our PANOVA-3 study where the patients received gemcitabine nab-paclitaxel doublet.

We believe this is an important trial first in that it gives us evidence in the metastatic setting beyond the locally advanced setting studied in our P3 study. And additionally, this allows us to gain insights into whether or not Tumor Treating Fields can provide a stronger benefit for atezolizumab in this setting.

We will also announce in Q2 2026 results from the TRIDENT study. TRIDENT is a Phase III study in newly diagnosed glioblastoma, adding Tumor Treating Fields as a therapy on both arms of the study. I think, I want to emphasize this point again, Tumor Treating Fields in TRIDENT is a backbone therapy and is not -- this study is one moment where the physician community around the world who treated glioblastoma, recognized Tumor Treating Fields is a standard of care and the trial is designed not to answer the question of does Tumor Treating Fields work, but how does it work best.

On the active arm of this study, we have moved Tumor Treating Fields earlier in the treatment paradigm than our existing approval such that Tumor Treating Fields will be used concurrent with radiation and chemotherapy. And in the control arm, patients will then wait to begin Tumor Treating Fields until the completion of their radiation and chemotherapy regimen.

So this is a question for the trial -- the trial is asking the question of how best to use Tumor Treating Fields within the glioblastoma setting, recognizing that Tumor Treating Fields should be backbone therapy for all patients.

Moving ahead, we are also conducting 2 large Phase III studies. First, we have our KEYNOTE D58 study, continuing our research in newly diagnosed glioblastoma. And leaning into our 2 unique benefits.

In this study, again, Tumor Treating Fields is viewed as a backbone therapy and is being used as the standard of care in both arms. In this study, pembrolizumab is being added as the active therapy on the interventional arm, giving us the chance again to study the effect of Tumor Treating Fields on taking a tumor such as glioblastoma, where pembrolizumab has failed as well as other immune checkpoint inhibitors have failed in multiple studies and asking whether we can produce a better response for patients. We are announcing here that we're pulling forward the expected LPI date for this trial to Q4 of 2026.

And lastly, within our R&D portfolio, I'll highlight that we are conducting our LUNAR-2 study in Phase -- our LUNAR-2 trial, a Phase III trial for the first-line treatment of metastatic non-small cell lung cancer. This trial builds on our prior result in the second line and brings the therapy forward to a first line again using concurrent pembrolizumab therapy in the first line.

We are looking at the study, as I've highlighted and brought forward, as we move forward at NovoCure, we will take a look at all R&D investments, including this R&D investment to understand how does it best fit within our understanding of the unique benefits of Tumor Treating Fields relative to what the other systemic therapies can bring to bear for the tumor.

So taking all of this together, let's look at the list of catalysts for 2026. First, in Q1, we have the release of top line data from the PANOVA-4 Phase II study in metastatic pancreatic cancer. Coming in Q2, we then released top line data from the Phase III TRIDENT trial in glioblastoma, and in Q2, we also anticipate the launch of Optune Pax for the treatment of locally advanced pancreatic cancer in the United States.

In Q4, we have 2 important milestones, one being the complete enrollment in LPI for Phase III of KEYNOTE D58, starting the follow-up clock for that trial. And additionally, our commercial launch following an anticipated regulatory approval for Optune Mya for the treatment of brain metastases from non-small cell lung cancer in the U.S.

We are also excited through the year to continue building on our existing business in glioblastoma, expanding our penetration in our existing key markets while also selectively finding those new markets where we can build a sustainable business that is both helping patients and contributing to our bottom line.

As we look at this together, our strategic road map is quite simple. We intend to drive adoption in our existing businesses in a financially responsible way, which will enable us to invest in and scale our portfolio through strong launches in both pancreatic cancer and in brain metastases. By extension, we've made the choices necessary to ensure that further investments into the commercial activities in our lung business will be appropriate given the demand curves that we've anticipated through our launch years.

We're also committing to ensuring that our investors hear us articulate a clear path to profitability as we move forward. Given that we have so many exciting growth opportunities ahead, it would be easy to simply state we're investing everywhere all the time to drive growth. That's simply not feasible as a device company trying to pioneer a new therapy. And so we are announcing here today that at our February earnings call, where we announced our full year result, we will provide guidance on both top line revenue and bottom line guidance on adjusted EBITDA, which we view as the first important milestone in our return to profitability. We want our investors to understand both our vision for growth as well as how we intend to accomplish that through financially prudent investments.

To take that one step further and just to share, as my role -- in my new role as CEO, how I think about the prioritization, we have to start first and foremost with the fact that our business helping GBM patients is what makes everything else possible. And we have to continue investing there, both on the commercial side as well as in our clinical portfolio, where we're going to bring important new evidence to bear through the TRIDENT and D58 studies. From there, we have to get our launches right in pancreatic cancer as well as in brain metastases.

Putting those 2 priorities against this commitment to the path to profitability and our drive towards adjusted EBITDA breakeven. We will review our R&D portfolio to ensure that our R&D allocations fit first and foremost with our top priorities, and we'll make additional announcements and details available as we move forward in the coming quarters on those decisions that we will take.

Taking all of this and taking just one step back, I'll close by highlighting that Tumor Treating Fields is now in its 25th year of development. The technology was -- the insight was developed by our founder, Professor Yoram Palti. And unfortunately, Professor Palti passed away this week. He passed away knowing that tens of thousands of patients have benefited from his technology, having met several of them. And I think that's what's always been unique for those of us who have joined NovoCure is the fact that all of us are here today at JPMorgan because we want to advance the future of medicine. And for those of you in the room who are focused on oncology, we really want to advance survival.

Specific to NovoCure, what I'm proud of is that because our therapy brings these differentiated effects that are not based on a systemic medical effect, we've been able to go after those tumors where we've seen failure after failure after failure. And while I will acknowledge as a device in the oncology world, we do sometimes swim upstream of physicians who want to use drugs first. We think that we have these unique attributes of a therapy that can't be replicated that give us; number one, a clear path to commercialization in our key markets, and number two, as you've seen in our GBM business, strong durable businesses that grow continuously.

GBM, we've been in market in the United States for 10 years, and we're still posting growth. We've defended our profit margin and our pricing in the United States over 10 years. And so I think as you think about NovoCure, while there are challenges of being the device in the oncology world, it also produces the durable moats around the business that we intend to lead into in the coming years and do that as we try to continue the mission that we started on that Professor Palti set us on 25 years ago.

So with that, Jess, I'll turn it over to you for questions, and I'll invite my colleagues Bill Doyle, our Executive Chairman; and Christoph Brackmann, our CFO, to come and join me.

Great. Thanks for that [Operator Instructions] but I'll start. So Frank, as you've taken the helm as CEO, can you talk about what your goals are for NovoCure and kind of what's likely to change and what's going to remain the same under your leadership?

Thank you. Yes, it's I think I'll start with what's going to remain the same. I think that we are a company that thrives on tackling these aggressive tumors and taking shots where we think we can really move the needle in cancer. So we you don't see us trying to pick up the easy indications. I think we will continue to operate where we think there's very high unmet need.

But to reiterate, as I stepped in, I think the challenge we've had in the past is that because our therapy has worked in every cell line, in every animal model, it's really easy to convince yourself that you can tackle every tumor type.

And my mantra to the team today and over the last 2 months is really lean into the fact that we have differentiated benefits that we bring. And that should carry through both to the marketing materials of really explaining the therapy through this biophysical lens through the failure of past drug trials to address tumor types. And then as we undertake our efforts to review our existing R&D portfolio to think through what does that mean going forward about how we invest the next R&D dollar.

So you highlighted the growth in GBM. And at the moment, it's sort of the core revenue driver, what gives you confidence in kind of sustaining this growth in '26?

I would say, I think it's -- I always think of it as 2 things coming together. I think on the one side, right now, through hard work over the last 2 years, we've done the operational effort to bring us to this moment. And what do I mean by that? We have reinvested in our sales and marketing teams in GBM to ensure that they're in the best position to find the physician and the patient at the moment that the treatment decision is being made, not just on the pure operational side.

We've also put ourselves in a really successful position to have the TRIDENT study, which is largely run by radiation oncologists, has just closed out this last year still has patients either on or now off, but in follow-up. And that trial over 2 years gave us direct engagement on the clinical side to all of the rad oncs with CNS experience. We then couple that trial, as it was closing, opened the D58 study setting pembrolizumab for GBM patients, which then put us into the academic sites.

And so if you look at 2025, we were engaging in academic sites that we haven't previously worked with. We were restrengthening our relationships with rad oncs who have previously driven our business. And we were doing that all on the back of really operational excellence in how we approach the position. And those trends we expect to continue. So that's kind of one side of the story.

The second side of the story of why I see our ability to drive growth is that, quite frankly, with every year that goes by, the evidence accumulates that Tumor Treating Fields is producing a stable, durable long-term effect for GBM. I would highlight that the Mayo Clinic across all of its health systems last year published a systemic review of patients over the prior -- I think it was prior decade, showing the Tumor Treating Fields had a statistically significant improvement in OS within their health system and including noting that it was producing durable, sustainable, long-term survival. So then we layer on top of that, we have TRIDENT reading out D58 coming up. I think we put ourselves in a place to build additional evidence over the coming years to keep this growth going.

Question in the audience?

Thank you very much for -- great presentation. Two questions, if I may. One, regarding pipeline beyond GBM and pancreatic tumor. I remember there were mesothelioma in the pipeline before. How are you thinking about what are the priorities besides challenges of the disease and bioavailability of the drug, how you're prioritizing? And the second question, our understanding is the main limitation of adoption has been some side effects regarding skin issues and battery packs, et cetera, any R&D effort in that to solve those problems, too?

Yes. I'll address the first part about R&D, but Bill, I'll actually ask you to talk about the product development side of this. So on the R&D to just continue on, when we think about -- so we do have an approval for mesothelioma in the United States. It's a limited approval under the humanitarian device exemption. We had the CE mark and have launched in Germany for mesothelioma. It's a relatively small indication to begin with and for us, it's a relatively small patient population. So we generally group it as we think strategically with our overall non-small cell lung cancer portfolio, recognizing they are actually different diseases.

What I would say is that we've seen over the last year, we know physicians who are interested in using Tumor Treating Fields for those diseases. We'll continue to support them. We're continuing to look incrementally for growth. We're not intending to open up any new investments either in MPM or as we move forward, we have our big investment in LUNAR-2 for non-small cell lung cancer. We're not at any time in the next couple of months, anticipating bringing forward a new concept in those areas because as I mentioned, in terms of prioritization, to be clear, funding is growth in GBM successfully launching the 2 new indications. And then within the R&D portfolio, figure out how we bridge to a path the profitability.

And thank you for your question about the product. we have the benefit that the therapy that Frank described so well comes with no systemic toxicity, so that's a plus. On the minus side, there is a patient burden and that's true. And the patient burden is associated, as you described, with one, as we attach these patches to the skin. Some patients have a skin sensitivity and exhibit contact dermatitis. And I said to everyone in the audience, if I put a band aid on your forehead for 2 years, chances are a number of you would get skin redness.

The other aspect of the patient burden is that they do have to carry this box. And today, the box weighs about a kilo, which doesn't sound like much, but if it's with you every day all the time, it's something that has to be dealt with and the patient has to overcome that. The good news for us is that we have a lot of opportunities to work on both of those patient burdens.

The first change that we'll make is an introduction of a next array that changes the skin contact material. And all of our testing to date shows that it's much less irritating on the skin. And I think we have an opportunity in the midterm here to really address that issue. We're also very focused on the box now, too, and we benefit from improvements in battery technology.

Quite frankly, we also need to look at product design historically, our box has been designed by electrical engineers, and it kind of looks like it was designed by electrical engineers rather than designed by CPG experts and our next generation will be smaller, will have a different form factor. And where we're also moving is to a combination device that is much more like a garment. So rather than patches that are either stuck to the head or the abdomen or the torso, it's going to be more like a garment that you take off and put on allowing patients to shower whenever they want and make it much easier. So we see a path to short-term real improvements in the arrays, medium-term improvements in the way the box is configured. And at the same time, moving toward a garment like device that just changes the use paradigm completely.

You touched on the TRIDENT study and that data coming up and how Optune is in both arms. So if that trial is successful, kind of encouraging the earlier use of Optune, how should we think about the incremental commercial opportunity that could be associated with that?

That's a fantastic question. I'll contextualize the data, and I'll ask Christoph, as our CFO, to talk a little bit about the downstream revenue opportunities. So the TRIDENT study to reiterate, is looking at moving Tumor Treating Fields earlier in the treatment of glioblastoma. So these would be patients who are newly diagnosed. And in the trial, they're randomized shortly after their diagnosis and then or shortly after finishing surgery before beginning radiation or chemotherapy.

This is a different population than studied in the EF-14 trial, which is our prior clinical study. And it specifically includes the group of GBM patients who typically progress quickly through radiation therapy, which has historically been about 25% of the patient population.

I bring that up to help contextualize the data because it's a different -- I want to emphasize again, it's a different patient population than EF-14 and cross-trial comparisons should not be made in that setting because 1 trial TRIDENT includes patients expected to progress quickly, whereas EF-14 were patients who started at a stable position and use Tumor Treating Fields.

So I say all that to say that, first and foremost, the TRIDENT study introduces Tumor Treating Fields to that additional 25% of patients, we simply don't see today. So if physicians begin Tumor Treating Fields during radiation therapy, they have, on average, 25% more patient population to select from. Now for that population, we do think duration may be slightly muted because obviously, they will progress. However, for those patients for the other 75% of patients who will benefit -- who will be stable, we do expect that we'll produce better duration of therapy overall than in our prior study. So it's a bit of a mix of puts and takes but when you look at all of them, they're all on the positive side.

Yes. And maybe to quantify a little bit more. So as Frank said, we charge for our therapy on a monthly basis, right? So longer duration directly translates into higher revenue for us. So on the one hand, we would expect because patients would start with a treatment journey about 2 months earlier. That's about 20% additional duration just from starting earlier. Then the other question that we don't know is what will be the additional benefit on being maybe longer on therapy because of additional efficacy. And the other area of where there could be a benefit is by starting more patients earlier, albeit with maybe longer -- smaller duration for the total population.

And if maybe I can add one more point around TRIDENT. Today, the GBM patient journey starts with usually a seizure than an MRI, then they go to a surgeon, then they get this 2 months of chemoradiation from a radiation oncologist and then they get their maintenance chemo from a medical oncologist. As Frank's described, our best prescribers are radiation oncologists. They understand physical modalities. If the point of prescription is the point where they're directing therapy. That's also a potential advantage for us in addition to the advantages that Christoph described.

Yes, makes sense. And then heading into the PANOVA-4 data in metastatic pancreatic cancer, what would be the next steps there and assuming or encouraging data? And what are the benchmarks we should look at when we interpret that data set?

Yes. So we -- okay. So to start with the benchmarks. We've pointed investors to the study by Dr. Dan Von Hoff and his colleagues that established approximately a 50% disease control rate for that patient population. And disease control rate is our primary endpoint. So we think we're coming in while the trial is a single-arm Phase II study, it is one that will be well understood within the historical context of results.

And I think what comes next is that we'll have to -- we do have to see the data to look at pathways forward. The landscape for the treatment of metastatic pancreatic cancer is obviously evolving minute by minute. I haven't followed what happened in the last 10 minutes here. We're very aware of that. And we're aware of the evolution of the RAS inhibitors. We'll need to see the benefit from an immune therapy, and we have multiple pathways forward to design our next study in pancreatic cancer, noting that objective response rates with the RAS inhibitors are still at best hitting around 50%, which means there's a strong need to augment the therapy. And noting that we're talking about taking patient survival in the 6- to 8-month range and trying to move the needle. That's a long way to go to getting patients to having 5-year survival.

Yes. Maybe in the last 20 seconds, I'll add to that. We're really excited to see these data with checkpoint inhibitors. But we've always described Tumor Treating Fields as a modality that can be combined with whatever the best pharmacology is so we've already started work of Tumor Treating Fields plus RAS inhibitors as well. And at least preclinically, it's very promising.

Great. so we'll leave it there. Thank you.

Thank you.

Thank you.

Good day, and thank you for standing by. Welcome to the Novocure Third Quarter 2025 Earnings Call. [Operator Instructions] Please be advised, today's conference is being recorded.

I would now like to hand the conference over to your speaker today, Ingrid Goldberg. Please go ahead.

Good morning, and thank you for joining us to review Novocure's third quarter 2025 performance. I'm on the phone this morning with our Executive Chairman, Bill Doyle; CEO, Ashley Cordova; and CFO, Christoph Brackmann. Other members of our executive leadership team will be available for Q&A. For your reference, slides accompanying this earnings release can be found on our website, www.novocure.com, on the Investor Relations page under Quarterly Reports.

Before we start, I would like to remind you that our discussions during this conference call will include forward-looking statements, and actual results could differ materially from those projected in these statements. These statements involve a number of risks and uncertainties, some of which are beyond our control and are described from time to time in our SEC filings. We do not intend to update publicly any forward-looking statements, except as required by law.

Where appropriate, we will refer to the non-GAAP financial measures to evaluate our business, specifically adjusted EBITDA, a measure of earnings before interest, taxes, depreciation, amortization, and share-based compensation. We believe adjusted EBITDA is an important metric as it removes the impact of earnings attributable to our capital structure, tax rate, and material noncash items and best reflects the financial value generated by our business. Reconciliations of non-GAAP to GAAP financial measures are included in our press release, earnings slides and in our Form 10-Q filed with the SEC today. These materials can also be accessed on the Investor Relations page of our website.

Following our prepared remarks today, we will open the line for your questions. I will now turn the call over to our Executive Chairman, Bill Doyle.

Thank you, Ingrid, and good morning. At Novocure, our mission is to extend survival in some of the most aggressive forms of cancer. Through our early years, our efforts focused mostly on the treatment of patients with glioblastoma. Now with one launch ongoing and 2 additional launches planned for next year, the scope of our mission has expanded to reach more patients who can benefit from Tumor Treating Fields in multiple solid tumor cancers. As we evolve from a single indication company to a true platform therapy company, we are focused on 3 priorities: First, preparing to treat 4 cancer indications by year-end 2026. Second, reaching profitability. And third, making disciplined investments that strengthen our product portfolio in the near and the long-term.

We will begin this morning with a review of our Q3 commercial results in glioblastoma and non-small cell lung cancer. We will discuss regulatory updates and preparation for anticipated launches in pancreatic cancer and brain metastases. And we will provide updates to our ongoing clinical and product development programs. We will conclude with a review of our quarterly financials and open the line for questions.

Our GBM business remains solid and active patients have grown between 5% and 12% year-over-year for the last 9 consecutive quarters. We ended the third quarter with 4,277 GBM patients on therapy, our largest patient count to date. The largest contributors to active patient growth in this quarter were France, Japan, and Germany, which grew 27%, 8%, and 7%, respectively.

We also expanded our international footprint. Last month, we received a positive national coverage decision from the Spanish Ministry of Health. At maturity, we expect Spain to deliver annual net revenue that is approximately half that of France. We expect full ramp-up to take a few years given the fragmented nature of the Spanish health care system.

In the U.S., our GBM active patient count was flat compared to Q3 2024. While we are proud to be treating approximately 40% of GBM patients in the U.S., we recognize that many more patients could benefit from TTFields therapy. Unlike lung cancer and pancreatic cancer, where most patients seek treatment in community centers, virtually all GBM patients undergo brain surgery at high-volume academic centers after diagnosis.

Oncologists at academic centers often prioritize enrollment in pharmaceutical clinical trials over new medical device-based therapies. This dynamic limits the number of patients offered Optune Gio in academic centers despite the established clinical benefits of TTFields therapy. Our commercial team continues to refine its approach within this complex environment, and we remain committed to ensuring that all eligible GBM patients are offered Optune Gio therapy.

Turning to non-small cell lung cancer. We've acknowledged that our launch is behind expectations. And in Q3, we did not see a continuation of the linear growth we've seen in the prior 2 quarters. While we anticipated lung cancer would be our most challenging indication to launch, it has been harder than we expected. We finished Q3 with 100 lung cancer patients on therapy, 94 in the U.S. and 6 in Germany. What makes advanced lung cancer particularly challenging is the poor overall health status of these patients, the high level of competition from new targeted drug therapies, and the limited median duration of therapy, 4 months versus the 10 months for newly diagnosed GBM.

We experienced similar launch challenges in 2011 with our initial launch in recurrent GBM when we introduced our device-based therapy to the neuro-oncology community in an advanced cancer setting. With GBM, we learned that consistent education and follow-on data generation drives prescriber and patient adoption over time. We are anticipating a similar path in lung.

To delve deeper, lung cancer is a highly competitive space. The survival benefit demonstrated in the LUNAR Phase III trial remains among the best reported in the post-platinum setting. But the number of systemic drug therapies available across settings makes the transition to a novel device-based modality like Optune Lua seem like a heavier lift for both physicians and patients. Our sales team is tackling this by highlighting specific patient profiles to help physicians better understand where Optune Lua is likely to provide the best benefit. Our primary focus is on patients who have had a durable response to a checkpoint inhibitor plus a platinum doublet and have slow progression with a maintenance checkpoint inhibitor.

There is also the challenge of introducing a device-based therapy to a medical oncology community that has limited device experience. As mentioned, we faced a similar hurdle when we introduced Optune Gio to recurrent GBM. And we know it takes time and hands-on experience for physicians to gain comfort with a device-based therapy. Simply put, a wearable device is novel in the oncology space. And as such, we are connecting experienced Optune Gio and Lua users who can share expertise and tips based upon real-world use with physicians new to the therapy to simplify the integration of Optune Lua into their practices.

Looking to the near-term future, an important upcoming milestone for Optune Lua is our Japan launch. Last month, we received approval from Japanese regulators for the use of Optune Lua and checkpoint inhibitors in advanced or recurrent non-small cell lung cancer. Japan has been a consistently strong region for Novocure, and we are planning for strong physician adoption of Optune Lua. We believe a high prevalence of lung cancer, Japanese physicians' appreciation for device-based therapies, and a local standard of care, which frequently utilizes immune checkpoint inhibitors in the first and second lines, provides the conditions for a successful launch in Japan. We will be closely monitoring the dynamics of our Japan launch to inform future strategies.

Longer term, we are working on 2 core programs to reach more non-small cell lung cancer patients, LUNAR-2 and product development. LUNAR-2 is our Phase III trial studying the use of Optune Lua plus checkpoint inhibitors and platinum-based chemo as a first-line treatment for newly diagnosed non-small cell lung cancer. Assuming success, LUNAR-2 will allow us to treat first-line lung cancer patients with Optune Lua and a checkpoint inhibitor, the drug device combination demonstrating the best efficacy across indications. Our product development efforts are focused on making the Optune device easier for patients to use through near-term improvements in support services, software and array design and longer-term efforts to design a transformative next-generation device.

It is critical to underline, we believe our efforts in lung are worth it. The investments we are making for the lung cancer indication also paved the way for our anticipated launches in pancreatic cancer and brain metastases in the next 12 months.

In summary, our core GBM business continues to grow, reaching more patients in more regions. Our lung cancer launch has been more difficult than anticipated, and we are learning and adapting our tactics. We have 2 additional launches in cancer indications with extremely high unmet needs anticipated in 2026, where minimal therapeutic options are currently available and that we can access with limited incremental investment as our lung cancer and GBM infrastructures will be leveraged. We are confident in our strategic direction, the strength of the clinical data supporting the use of TTFields therapy, and our plans to achieve profitability.

With that, I'll turn to Ashley to provide an update on our regulatory and clinical progress.

Thank you, Bill. Earlier this year, we had an exciting presence at the ASCO Annual Meeting where data from PANOVA-3 were presented during the Saturday evening plenary with concurrent publication in the Journal of Clinical Oncology. In July, the PANOVA-3 results earned a second podium presentation at ESMO GI, where the quality-of-life data was described in greater detail. PANOVA-3 demonstrated Tumor Treating Fields' ability to extend survival and preserve quality of life in pancreatic cancer, yet another aggressive solid tumor where Tumor Treating Fields has shown a benefit.

In August, we submitted our PANOVA-3 data in a PMA package to the FDA for the treatment of unresectable locally advanced pancreatic cancer. The filing was accepted, and we are currently in the substantive review phase with our FDA 100-day meeting scheduled for mid-December. The review is proceeding as anticipated and in line with our previous experience, we expect FDA approval mid next year. In September, we also initiated the PANOVA-3 filing process with European regulators and are currently preparing our filing in Japan. The pancreatic cancer treatment landscape is similar to GBM where effective therapeutic options are extremely limited. Feedback from leading pancreatic cancer physicians and advocacy groups on the PANOVA-3 data has been consistently positive, and we look forward to the opportunity to treat pancreatic cancer patients as soon as possible.

Moving to brain metastases. We presented the final data from our Phase III METIS trial in the plenary session at the 2025 ASTRO Annual Meeting in September, and these data were concurrently published in The Red Journal, the leading publication of the radiation oncology community. ASTRO is an important conference for Novocure as it hosts the largest gathering of radiation oncologists annually, a group of physicians that historically have best appreciated the benefits of Tumor Treating Fields therapy. This year, the METIS presentation was 1 of only 5 plenary selections out of 2,500 submitted abstracts, underlying the community's interest in our METIS data. There is a palpable excitement among radiation oncologists in the potential of Tumor Treating Fields to better control brain metastases given their experience using Optune Gio to treat GBM.

The first 2 modules of the brain metastases PMA have been submitted to the FDA. We received questions from the FDA regarding our second module, and we are working to close these questions out swiftly. We are prepared to file the third and final clinical module as soon as those questions are resolved. Our timeline for the full PMA submission is unchanged, and we continue to expect to complete the filing by year-end 2025. Like the pancreatic cancer filing, we expect a 9- to 12-month review once the clinical module is accepted by the FDA with the final decision anticipated in the second half 2026.

As Bill discussed, the investments in our lung launch have established the infrastructure needed to launch both the pancreatic cancer and brain metastases indications upon regulatory approval. We expect to launch these 2 new indications by leveraging our existing sales forces. The team detailing GBM will detail brain metastases and the lung sales force will detail our pancreatic cancer indication. We also see significant opportunities to leverage our medical education efforts, creating synergies across tumor types that accelerate awareness and deepen engagement within the medical oncology community. We expect our existing infrastructure to provide a strong foundation for these new indication launches without the need for substantial additional investment.

Turning to product development. An enduring reality of virtually all cancer therapies is a trade-off between extending survivals and the burdens and side effects of receiving cancer care. An overarching goal of our product engineering efforts is to minimize any potential burden of the Optune users' experience, either through improved devices or complementary offerings. We are pursuing projects to improve the therapy experience for cancer patients and physicians across all indications and expect to improve the Optune experience…

[Technical Difficulty]

Ladies and gentlemen, please standby, your call will resume momentarily. Once again, ladies and gentlemen, please standby, your conference call will resume momentarily. You're back online, you can resume.

All right. I am going to pick up at the product development conversation. Okay. Welcome back, everyone.

Turning to product development. An enduring reality of virtually all cancer therapies is a trade-off between extending survivals and the burdens and side effects of receiving cancer care. An overarching goal of our product engineering efforts is to minimize any potential burden of the Optune users' experience, either through improved devices or complementary offerings. We are pursuing projects to improve the therapy experience for cancer patients and physicians across all indications and expect to improve the Optune experience in both the near and longer term.

Earlier this year, we launched a new patient app in the U.S., which provides patients and caregivers a central location to track their Optune Gio usage, reorder new supplies, access FAQs and contact Novocure. Over 78% of U.S. GBM patients are users of the new app, and we are now preparing to launch in our international markets.

On the physician front, we launched a new portal for GBM prescribers this year, which streamlines the prescription administration and ongoing care processes. Over 60% of our target sites are active on the portal and physicians and their care teams tell us that they are pleased with the simplified administrative processes. We also recently submitted our updated MAXPOINT GBM treatment planning software for use with the HFE arrays to the FDA and expect approval in upcoming months.

As a reminder, the MAXPOINT algorithm uses patient MRI scans and physician inputs to create individualized optimized array placement maps as a function of the electrical properties of a patient's brain tissue. MAXPOINT received a Category III CPT code in July, and we plan to launch it as a product enhancement subsequent to FDA approval.

On the array front, we have rolled out our HFE arrays in all material markets and expect to fully complete the global rollout by year-end. We are also in the process of bringing many of the HFE array design elements and materials components into our next-generation torso array, which we expect to submit to the FDA for approval next year. As a medtech company, we have the unique opportunity to increase adoption and advance patient outcomes from both product and clinical development.

Of note, we have 2 clinical readouts expected in the first half of next year. The Phase II PANOVA-4 trial in metastatic pancreatic cancer should report out in late Q1 of next year. And the Phase III TRIDENT results in GBM will follow in Q2. PANOVA-4 will add to the existing pool of data exploring Tumor Treating Fields plus an immunotherapy chemo combination regimen, but for the first time in metastatic pancreatic cancer, which continues to be a devastating diagnosis for patients and their families.

TRIDENT studies the benefit of starting Tumor Treating Fields concurrently with chemo radiation in newly diagnosed GBM rather than waiting until after a patient's chemo radiation cycle ends. The goal of TRIDENT is to improve Tumor Treating Fields' ability to enhance the cancer cell DNA damage mechanisms of radiation. If successful, TRIDENT could enable radiation oncologists to prescribe Tumor Treating Fields earlier in a GBM patient's therapy journey than a standard of care today, something we know to be important. Data from these trials will further elucidate how Tumor Treating Fields can best be harnessed to improve the lives of patients diagnosed with these deadly cancers, and we are excited to share these results with you early next year.

As we look ahead to 2026, we are on the verge of becoming a true platform therapy company. With 4 indications expected in market by year-end 2026, our teams are excited about the opportunity to treat many more patients in need and continue our pursuit of profitability in the year to follow.

I'll now turn the call over to Christoph to review our Q3 financial performance.

Thank you, Ashley. We continued our positive momentum this quarter with net revenues of $167 million, an increase of 8% from the third quarter last year. This was primarily driven by year-over-year active patient growth of 5% in our GBM franchise, notably by strong performance in France, Germany, and Japan. We also had a foreign exchange rate tailwind this quarter of $3.3 million compared to the same period in 2024. We collected $3.1 million from Optune Lua claims in the quarter, including $1.6 million from non-small cell lung cancer collections in the period. As a reminder, reported revenues from non-small cell lung cancer reflect cash collections from approvals and positive outcomes from appeals in the quarter.

Gross margin for the third quarter was 73%. The reduction in margin is reflective of the global rollout of HFE arrays, the ongoing launch in non-small cell lung cancer, where we are treating patients prior to establishing reimbursement and increased tariffs. In the quarter, we also recognized a $2.9 million expense related to an inventory obsolescence provision for Optune Lua arrays.

Moving to operating expenses. Our research and development costs in the quarter were $54 million, an increase of 4% from the same period last year. We do not expect R&D expenses to increase materially this year as we ramp down spend on PANOVA-3 and METIS and reallocate those funds to KEYNOTE D58 and LUNAR-2.

Sales and marketing expenses in the quarter were $59 million, a decrease of 2% from Q2 of last year. This decrease was driven by lower share-based compensation expenses. As disclosed in prior quarters, we expect to leverage our current sales force to launch our pancreatic cancer and brain metastases offerings in 2026, pending FDA approval. G&A expenses for the quarter were $46 million, an increase of 15% from Q3 of 2024. This increase was primarily driven by higher share-based compensation expenses and higher personnel and professional service expenses to support the greater company build-out, particularly in enterprise technology as we invest in our digital infrastructure to enable scale.

Net loss for the quarter was $37 million with a loss per share of $0.33. Adjusted EBITDA in the quarter was negative $3 million. While still negative for now, adjusted EBITDA is currently ahead of our internal plans for the year, driven both by solid revenues from our GBM franchise as well as constant prioritization of investments. We are committed to breaking even sustainably on an adjusted EBITDA basis in 2027 with the revenue contribution from new indications.

Our cash and investment balance at the end of Q3 was $1.034 billion. As a reminder, we have a $561 million in convertible notes that will come due in the coming days, which we will retire with cash from the balance sheet. We also closed on the second $100 million tranche of our credit facility this quarter. With the cash and short-term investments currently on the balance sheet and funds available through our credit facility, coupled with ongoing expense management, we continue to believe that we have the capital necessary to bridge to our next revenue streams in new indications.

At Novocure, we are on the cusp of expanding the reach of Tumor Treating Fields to patients in multiple solid tumor cancers. The discerning investments we are making today establish an infrastructure capable of treating patients in multiple indications. We look forward to the future treating more commercial patients in established and new geographies, 2 important data releases in the first half of 2026, and pending approvals in additional indications with high unmet need. And importantly, we are confident in our ability to achieve profitability.

We will now open the lines for questions. Operator?

[Operator Instructions] Our first question comes from Jason Bednar with Piper Sandler.

I wanted to start first here on lung. A few questions here. I'm just going to pack in. The launch in Germany and Japan, I know it's super early days, but any comparisons you can make relative to the launch trajectory you have here in the U.S. as we think about how those markets could scale relative to how the U.S. has performed? Anything that you can take with the slower ramp and adjust the go-to-market strategy outside the U.S.? And then I'm wondering if there are other factors outside of just physician education that might be helpful here in the U.S., such as securing reimbursement and/or inclusion in NCCN guidelines? Can you help me with where you stand on those fronts?

Great, Jason, this is Ashley. I'll start and talk a little about the global footprint, and then I'll ask Frank to jump in with the specifics in the U.S. I think really in Germany, what I would say is it's still very early days. We're just now entering into the beginning of our third quarter there and the summer periods in Europe are a thing. So as we look ahead, I would say, there is no new news coming out of Germany that we've seen that kind of differs from the dynamics we've seen in the U.S., both in the opportunities to continue to drive growth and in some of the challenges that may come in this education. But I would not point to anything specific in those early numbers and say it's early days, and our teams are there executing and building those relationships.

When we look ahead to Japan, we do think that this is a very different market for Optune Lua. We have received approval for Optune Lua in Japan, but we have not yet received national reimbursement. That means our field teams are able to begin the physician education process, but the real launch dynamics will come to bear when we do have physician reimbursement, which we anticipate in upcoming quarters. But it is a market we believe will be different for us and an easier market to launch in for a couple of factors that Bill mentioned on the script.

The first of which is that there is just a much higher prevalence of lung cancer in Japan. The second of which is the Japanese physicians are more comfortable using device-based therapies, I would say, across the board. The third of which is that we have a local standard of care, which is extremely comfortable using ICI across all settings, both first and second line. And on the top line growth format, because we have a single national payer, once we get reimbursement, we're able to see that active patient growth translate to bottom -- to top line and bottom line growth quite quickly. So we are preparing for that launch. And again, we're quite hopeful that it will be materially different than the trajectory we've seen in the U.S. and Germany.

Hello, Jason, this is Frank. Thank you for the question. To pivot back to the U.S. and talk about learnings and tactics, I think one thing we would acknowledge is in the launch, we initially pursued large volume academic practices where you do see large populations of Stage IV non-small cell lung cancer being treated because, obviously, you're trying to go after the patient volumes that you can capture. And the challenge that we found in that setting is that, #1, they're just not comfortable with devices as a starting point. And so you're introducing a new workflow, a new modality into the practice.

What we have found more effective as we pivot is in those larger volume practices, you can find the doctor who perhaps is seeing Stage III, but occasionally is consulted on Stage IV and is hyper interested in Tumor Treating Fields. And so we do have an example of one large academic practice where starting with somebody who is seeing 1 or 2 patients a month, they're now consistently prescribing 3 or 4 patients a month because they're pulling them in from the med on practice. And so we're trying to lean into that tactic right now of not necessarily finding the doctor with the highest volume, but finding the highest interest and their willingness to be an advocate within their practice to pull it in. So thank you, and happy to provide more color.

Maybe just as a quick follow-up, anything on commercial reimbursement to get updated on and anything on NCCN guidelines that we should be monitoring? And then as a follow-up, and this has been pivoting hard, but in Spain, I know you referenced that as a market that has a different structure to it. It's going to take maybe a little bit longer than France to ramp up. I think probably maybe a bit more normal or comparable to Japan back in the day. But I guess with the trajectory of that adoption, is that something we should expect to be linear? Or is it more back-end loaded? How to think about that ramp-up when it starts happening?

Yes. So Jason, this is Ashley. On the NCCN guidelines, just as a reminder, we submitted at the end of last year. We know that the package and the application was reviewed in early July, and we would expect the updated guidelines to be published in the upcoming months. We really don't have any more insight on the progress there beyond that. I will note that in the commercial setting, which is where we're now able to submit for reimbursement and approval, we are seeing, honestly, approval rates above our internal expectations. So this is going well. In lung, the payers are responding to the strength of the data. We would expect that to continue to be the case in all scenarios.

I think the real unlock on the reimbursement side for lung will be Medicare, of which the NCCN guidelines is a key input, but it's not the end of that journey. So I think commercial reimbursement going well. Medicare, a much longer journey, which we started and which NCCN guidelines will support.

In Spain, I think it is a good reference to the Japan rollout of Optune Gio 7 years ago because we do have to contract hospital by hospital despite the national reimbursement. So it really is, I would say, in an administrative processing phase. Time will tell. What we said is that we think it won't flip on overnight, but it will ramp up over the course of a couple of years. And I think it will be a continuing driver of top line growth for us, both in the active patient numbers and in revenues over the next 2 years.

Our next question comes from Vijay Kumar with Evercore ISI.

This is Kevin on for Vijay. I have a few more questions on lung. You've talked about the launch being behind expectations. Are you able to share what your initial expectations or targets were for lung? And second, on LUNAR-4, would you say this termination is at all connected to your latest views on the lung cancer market broadly? And lastly, if you can share the year-to-date spend on that program before it was terminated?

Yes, Kevin, this is Ashley. Thanks for the question. Unfortunately, the answer to all of those is, I would say, no, meaning we're not able to share that level of detail, and we're not sharing the internal launch expectations. What I will say, though, what we can say is that we always knew that this would be a slower ramp than it would be if we were a little white pill. We know that across our device. Linear growth was what we anchored people to. And now what we're saying is we knew it would be hard. It's somewhat harder than we would expect it -- than we expected, but we do continue to look ahead to growth. And again, I would point both to ongoing trajectory in the U.S. and Germany and to hopefully a step function increase in that growth from Japan. So that's where we are with LUNAR overall.

With LUNAR-4, the story there really is about actually the disciplined investments and what we were able to save by looking at the ability to gather that data from real-world evidence, which, in the U.S., I will remind you that approximately 90% of our patients on Optune Lua for non-small cell lung cancer have had prior ICI exposure. So we are able to look at the real-world evidence and the experience in the U.S. and publish over time that data to answer a very similar question than LUNAR-4 was asking. So we do know it is still a very relevant scientific question. We are committed to kind of exploring that question, but it is a far more cost-efficient way and for us to do that through real-world evidence.

Yes. Vijay -- Kevin, sorry, this is Christoph. Just to add to what Ashley said, the savings that we expect is in the mid to high single-digit million. So it's actually a quite worth achievement.

Our next question comes from Jessica Fye with JPMorgan.

This is Tanmay on for Jess. My first question is we now know that active patients for non-small cell lung cancer grew to 100 in 3Q. But given the sequential decline in prescription, could you probably just expand on the underlying dynamics there? And second question would be if you could expand on the gross margin trajectory? And over what time horizon can we think about that recovering or maybe even exceeding historical levels?

Sorry, could I just to clarify the first question around prescription and patient volumes? Didn't quite…

Yes. So for the non-small cell lung cancer, we now have 100 patients in 3Q. However, we see a sequential decline in prescription volume. So could you maybe just expand on the underlying dynamics there?

So thank you for the question. So yes, we -- what we do see is that we focus internally, our big focus is on active patients. There's always a bit of noise in prescription volumes because it's a question of some practices write prescriptions before they've really educated the patient. Some practices only write the prescription when they're ready for the patient to start. And I think we need a few more quarters in lung cancer before we really settle into what a fill rate would look like. So for right now, I would ignore the noise around prescriptions.

I can take the question on gross margin. So we had -- maybe just to take a step back, in the quarter, we had a gross margin of 73%. At the beginning of the year, what we said is what we would expect during the year is the gross margin to come closer to lower 70s, driven by a couple of headwinds. One is the rollout of the HFE array. Two is -- basically was the lung cancer indication where we launched before getting reimbursement. And then there was another headwind that came to it, it was tariffs. So if you now look at it all together, we're actually pleased with the cost reduction journey that we have been able to accelerate on the HFE arrays. So as a result, for this year, we see the gross margin get closer to kind of the mid-70s as opposed to the lower 70s.

Now when we look ahead, our gross margin will be impacted by the launches and the launch trajectories. And it really comes back to the fact that in order to get reimbursement, for us, it's a process. It doesn't come with approval. And we will be starting to treat patients in markets where we expect to be reimbursed before we have the actual reimbursement. So there will be a lead time -- there will be a gap between starting off patients and getting reimbursement, and that will impact our gross margin. And quite honestly, the more successful we are, the more it will impact the gross margin during this transition period. Now I think what's important is we are somewhat in control of this because we can accept the patients or not accept the patients if you don't get the reimbursement in the time line that we want. And so our gross margin, there will be a little bit of noise as we go through the launches. We expect it to come back to higher levels when we are through this period, which is in the higher 70s.

And I would just say, in all scenarios, when we look at profitability as defined by adjusted EBITDA, we remain committed to that path and can see getting there throughout those launches.

Our next question comes from Jonathan Chang with Leerink Partners.

This is [ Evelyn ] on for Jonathan. So one more on the Optune Lua launch in lung. So you reported 84 unique prescribers. Can you provide some clarification on whether that's specific to Q3 or that's cumulative since the launch or something else? And then one follow-up, if I may, on profitability. Can you provide more color on what goes into your goal of breaking even in 2027?

So Eva, that stat is specific to Q3. So that's an easy answer. And I will point out the takeaway there that it's been consistent across quarters. And what we're seeing is that we're able to bring both new prescribers into the Optune Lua treatment journey, and we're retaining existing prescribers. So when we think about that mix between new and returning, we see about a 50% split there, which is a nice trend as we look ahead. And I will also remind everybody, when we look at the profile of patients we're getting, we are seeing that patients approaching 90% of them have prior ICI exposure. So we're also seeing it used in a combination that we know is relevant.

Yes. And sorry, on the adjusted EBITDA, your line was a bit same. What exactly was your question?

Just more color on what goes into your goal of reaching the breakeven in 2027? Yes.

Yes. Okay. So first, I'd say this is really no change in messaging. I mean this is very consistent with our commentary in the past. What we said is that we would expect to breakeven on an adjusted EBITDA level at a revenue of around $700 million to $750 million. And the range is really explained by 2 main items. And the one is the level of R&D expenses, which is driven by the pace of enrollment in Phase III trials in essence. And 2, the dynamics that I just talked through in terms of during launch years, we have an impact on gross margin. Both levers are in our control. And so again, we expect to breaking even on an adjusted EBITDA level at a revenue level of $700 million to $750 million, and we expect this to be during 2027, we'll be there on a sustainable basis, meaning up to then, we could be close as this quarter, we were very close, minus $3 million. And we believe we'll be sort of bouncing around this breakeven on adjusted EBITDA level. During 2027, we believe we will be on a sustainable level.

Our next question comes from Emily Bodnar with H.C. Wainwright.

I guess on the lung side, I was curious with how the launch is going currently. Do you have any kind of internal changes to your expectations for what the opportunity could look like at peak and kind of more color on how we should be thinking about ramp maybe for next year? And also what learnings you've had from the launch so far that you can kind of use to make sure the pancreatic launch doesn't kind of fall into a similar pattern?

Emily, that's a great question. I'll start with a little bit of what our expectations are internally and then ask Frank to provide some of the learnings. But zooming out, lung is hard, but we do know it's worth it given the opportunity, both long term, but also across the entire portfolio. And the incremental cost for spinning is actually quite negligible when we look at the investment we would be making today versus the investments we need to be making for pancreatic and brain mets as we look ahead. So we have adjusted our internal expectations. We are making sure that we have motivated field teams that are focused on the right targets driving growth. But I will say when we look at investments, the investments we have made are investments in the platform, and they will establish that infrastructure that will treat the full portfolio over the next year.

So while we're always looking at those discerning investments, I will say we really are now looking at the platform. And again, we're confident that those are the right ones as we look to this path to profitability with top line growth coming from 4 products on the market in the end of the year. But I'm going to ask Frank to provide specifics on pivots in the market.

Yes. So thank you. So first, to go to the question around how do we view the long-term value. We still see the long-term value in helping non-small cell lung cancer patients. There's a tremendous unmet need in the second line. And as we look even further ahead to the LUNAR-2 trial, there's a huge opportunity within first-line treatment. And so for us, given the data set that we have, we believe we have a compelling reason to be in this market, helping the patients. In terms of learnings and pivots, I think Bill in his opening noted on the need for education and additional evidence as you work into a new community of doctors. And so on the education front, I think, one, we have the advantage that we are in market already.

So physicians are hearing about our lung indication, but by extension, when we go into and have approval to actually market to panc, they won't be naive to the messages. #2 is to take a direct learning from lung in terms of the education that we need to do, I'd say we've learned that we need to educate not just the physician, but the practice, the nurses, the physicians' assistants and really everyone in the practice on the therapy because you don't know where the patient will direct their question, the first question about the device. And so I think that's in the real tactical side of things, but it's things that we now know we need to do to be successful in our next medical oncology launch.

And then Bill also mentioned the need for continued evidence generation. I think one thing we've done for panc is ensure that at FDA launch, we're also in the process of closing out the PANOVA-4 data set. So trying to take those learnings and really lead towards an excellent launch in panc.

And I'm not showing any further questions at this time. I'd like to turn the call back to Bill Doyle for any further remarks.

Thank you, Kevin. I'd like to conclude the call where I began. Everyone in Novocure comes to work every day to help patients extend their survivals in these really aggressive cancers. We've been working very hard for years to help patients with GBM, and we are now excited and in the middle of our preparation to become a true platform company, serving, again, patients in 4 indications by the end of next year. Our pipeline is on track. We were very pleased with the clinical recognition we've received for PANOVA-3 and METIS. And on the financial front, again, we expect now 4 diversified revenue streams, and we're committed to marching forward toward profitability. So we have an exciting 15 months ahead, 6 major country-level launches, 2 important data readouts, and meaningful product improvements that we continue to focus on and we'll be rolling out.

So with that, I want to thank the Novocure team for all their hard work and for your attention and support today. Thank you.

Ladies and gentlemen, this does conclude today's presentation. We thank you for your participation. You may now disconnect, and have a wonderful day.